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INTRODUCTION 
 
Siddha system is considered to be one of the ancient system of medicine in the 
world. Siddha is a complete holistic medical system that has been practiced in India for 
two thousands of years above.  
 
The siddha system of medicine has derived its name from the word "Siddhi", 
which means "Perfection" or "Eternal bliss". Siddhi refers to the eight supernatural 
powers that are attainable by man. Those who attained these supernatural or perfection or 
Siddhi were called "Siddhars". They realised that if the body could be made strong and 
perfect, they could get rid of death and diseases. 
 
They have fully investigated and studied the cause and the effects of  
the diseases and all kinds of drugs, minerals and poisons. They imparted  
their knowledge for the upliftment of the suffering community.  
 
Panchapootha theory has also been described by Siddhars. The panchapoothas are 
Akasam or veli (ether), Kaattru or vayu (air), Thee or agni  (fire), Neer or appu (water), 
Nilam or piruthuvi (earth).  
 
Every form of matter has to be considered as panchapoothas in its orgin Vali 
( ) Azhal ( ) Iyam  ( ) are the three main Physiological regulators of the body 
and mind. They are called "Muththathukkal". They remain always in a state of equipoise 
in healthy individuals. Increase or decrease of one or more will cause disease.
ÁÕó¦¾É §Åñ¼¡Å¡ Â¡ì¨¸ì ¸Õó¾¢Â 
¾üÈÐ §À¡üÈ¢ Ôñ½¢ý.I
Generally when a medicine is administrated Siddha Physician prescribes diet 
regimen according to the nature of the medicine and severity of the disease. This is 
because over intake or consuming unbalanced and incompatible diet is considered to be 
the prime causative factor for upsetting the tridhosa balance leading to manifestations of 
various ailments.
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Jaundice originates from th yellow. It is a 
physical sign often characterized by yellowish color of the skin, tissues, eyes, and certain 
body fluids. It may result when excess amounts of a pigmented substance from old 
discarded red blood cells (bilirubin) dissolve in the layer of fat just beneath the skin 
(subcutaneous fat). Jaundice can be a symptom of other health problems also. 
 
Bilirubin is formed when a certain pigment (hemoglobin) in red blood cells breaks 
down as part of the body's continuing process of replacing old red blood cells with new 
ones. In normal circumstances this form of bilirubin (unconjugated bilirubin) is converted 
by the liver into conjugated bilirubin. Conjugated bilirubin becomes a component of 
digestive fluid (bile), and ultimately is eliminated from the body primarily in the feces. 
Jaundice occurs with elevated levels of either unconjugated bilirubin or conjugated 
bilirubin. 
 
Except for the newborn form of jaundice (caused by accumulation of discarded 
red blood cells), the condition is a symptom of overload or damage to the liver, or 
inability to move bilirubin from the liver through structures transporting bile (biliary 
tract) to the intestines. For example, overproduction of bilirubin from the breakdown of 
red blood cells (after internal bleeding or in bleeding disorders) may overburden the liver 
with more bilirubin than it can process or conjugate. Because unconjugated bilirubin 
dissolves in fats but not liquid, this form causes yellowing of the skin (hemolytic 
jaundice). Jaundice may occur in liver cancer (malignant jaundice) or infectious diseases 
(infectious jaundice) such as hepatitis or cirrhosis, where the damaged or inflamed liver 
cells are unable to convert bilirubin to the conjugated form. Obstructive or cholestatic 
jaundice occurs with blockage of the flow of bilirubin from the liver to the intestines.
Infectious jaundice due to hepatitis can result from varied causes such as bacterial 
or viral infections, infestation with parasites, chemicals (alcohol or drugs), toxins, or 
immune diseases. Some forms of infectious hepatitis are transmitted through blood 
products, eating contaminated food, sexual contact, and other unknown means. Over-
consumption of foods containing an orange coloured anti-oxidant pigment (beta-carotene) 
such as carrots and melons can create a yellowish skin condition called pseudo-jaundice, 
which generally does not produce other symptoms.II
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The formulation of "Sarakonraipoo Chooranam" is indicated for Kamalai, in 
Siddha text, "Gunapadam - Mooligai Vaguppu" by the Author Dr.K.S.Murugesa 
Mudhaliyar.  
 
Hence the author have selected the medicine "Sarakonraipoo Chooranam"  for 
treating Kamalai (Liver diseases).  
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AIM AND OBJECTIVE 
 
 
AIM:
Hepatoprotective Activity in the management of Kamalai (Liver disease).
 
OBJECTIVE:  
PRIMARY OBJECTIVE: 
To evaluate the Hepatopro
preclinical studies. 
 
SECONDARY OBJECTIVE: 
Biochemical analysis 
Activity in the management of Kamalai (Liver disease). 
 
Collections of evidences in siddha literature 
Collection of evidences in mineralogical  aspects. 
TLC 
Toxicological Study: 
Acute toxicity
Sub-acute toxicity 
Pharmacological Study: 
Hepatoprotective activity
Antioxidant property
Clinical study
A pilot study on trial drug
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MATERIALS AND METHODS 
 
 
STANDARD OPERATIVE PROCEDURE:  
Collection and Authentication of the raw drugs: 
The flower was collected from the forest, Vandalur, Chennai and authenticated by 
competent authority in HoD of Gunapadam. 
 
Ingredients:
Purified Sarakonraipoo
Purification process:  
Purification of Sarakonraipoo (Cassia fistula):III  
The inflorescence is purified by removing the stalk, sepals, androcieum, 
gynaecium and foreign particles. 
 
Preparation of the medicine: 
The inflorescence of Sarakonrai  was pulverized into fine powder by an electric 
grinder. And then it was sieved by using a fine silk cloth (Vasthrakayam). The fine 
powder was mixed with milk and backed in a backing pan (Pittaviyal Method). Then it 
was dried and ultra filtered by a cotton cloth and made into fine powder again. The 
powder was stored in a clean, dry, air tight glass container.  
 
LABELLING:  
Name of the preparation : Sarakonraipoo Chooranam  
Color     : Brownish Yellow 
Quantity of the drug  : 14 gm 
Dose    : 1gm, bid 
Adjuvant/ vehicle : Milk
Indication    : Kamalai (Liver disease)  
Date of manufacturing : 20/07/2012   
Date of expiry   : 3 months from the date of manufacture  
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REVIEW OF LITERATURE 
 
 
ºÃì¦¸¡ý¨ÈôâIV 
ºÃì¦¸¡ý¨È  
 
Classification:    
  Kingdom :   : Plantae  
Clade :   : Angiosperns  
Class    : Dicotyledons  
  Sub-class         : Polypetalae  
  Series      : Calyciflorae  
  Order    : Rosales  
  Family    : Caesalpiniaceae  
  Genus      : Cassia  
  Species     : C.fistula  
  Botanical name : Cassia fistula. Linn
  
§ÅÚ¦ÀÂ÷:
¦¸¡ý¨È
¦¸¡ñ¨½
¦ÀÕí¦¸¡ý¨È
¸¢Õ¾¡ÁÄõ 
¾¡Áõ
Á¾¨Ä
¾Æ¢
¸Îì¨¸
¬ìÌÅ¾õ  
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À¢È¦Á¡Æ¢¸û:  
  English  : Indian ladurnam,  
    : Pudding-pipe tree,  
    : Purging cassia,  
    : Purging fistula  
  Telugu  : Rela-kayulu  
  Malayalam  : Konna  
  Arab    : Khiyar-shanbar  
  Pers   : Khizar-chanbar  
  Hindi  : Amaltas  
  Kannada  : Kakke  
  Sanskrit  : Aragvadham 
ÀÂýÀÎõ ¯ÚôÒ:  â, ¨Ä, Òª¢, Å¢¨¾, ÁÃôÀð¨¼, §Å÷ôÀð¨¼ 
â:  Í¨Å   : ÐÅ÷ôÒ  
  ¾ý¨Á  : ¦ÅôÀõ  
  À¢Ã¢×   : ¸¡÷ôÒ  
¦ºö¨¸:  
  ÒØì¦¸¡øÄ¢  ¸¢ÕÁ¢¿¡º¢É¢ Vermifuge 
¦À¡ÐìÌ½õ:
â×ìÌ ¦Åû¨ª, ¦Åð¨¼, À¡ñÎ, ¸¡Á¡¨Ä , ¦º¡È¢, ¸ÃôÀ¡ý, §¾Áø, 
Ì¼øÅÄ¢ ¬¸¢Â¨Å ¿£íÌõ.
§ÁÖõ ÅÂ¢üÚôÒØ, ¿£Ã¢Æ¢×, Ì¼¨ÄôÀüÈ¢Â §¿¡ö¸û §À¡õ.
ÁÄì¸¢ÕÁ¢ §À¡Ìõ Á¾¢¿£÷ì Ì¼Ä¡ó
¾ÄòÐ§¿¡ ÔíÌ¨ÄóÐ º¡Ôõ - ¿¢Äò¾¢üÌû
±ý¨ÈìÌõ Å¡¼¡¾ Å¢ýÀ ÁÄ÷ì¦¸¡õ§À
¦¸¡ý¨Èô ÀÍÁÄ¨Ãì ¦¸¡û.
ÅÆìÌ:
â¨Åò ¾É¢ò§¾Ûõ, ¾ý ¦¸¡ØóÐ¼ý §º÷ò§¾Ûõ «¨ÃòÐô À¡Ä¢ø 
¸Äì¸¢Ôñ¼¡ø ¦Åû¨ª, ¦Åð¨¼, ¸¡Á¡¨Ä , À¡ñÎ Ì½Á¡Ìõ.
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Cassia fistula ExtractV 
 
Active Ingredient :  
Anthraquinones 1.5% & Fistulic Acid 
 
Common Name :  
           Fistula, Laburnum, Purging Fistula, Golden Shower 
Chemical Constituents and Components :  
Main chemical components are anthraquinones, fistulic acid, rhein, rheinglucoside, 
sennosides A and B, phlobaphenes, emodin, chrysophanic acid, fistuacacidin, lupeol, 
beta-sitosterol and hexacosanol.  
Actions:  
Anthroquinone: 
           1. It decreases the amount of enzymatic cytochrome C reduction at low 
concentration of NADH.  
           2.  It shows good Antineoplastic Activity.  
           3.  It inhibits the Catalytic Activity of Topoisomerase II.  
           4.  It shows clastogenic effect on bone marrow cell and used as weak genotoxic.  
Fistulic acid: 
1. It significantly lowers the serum levels of transamineses (SGOT and SGPT).  
2. Bilirubin and alkaline phosphatase (ALP).
3. It significantly lowers the lipid level in blood and liver.
4. It significantly decreases the high activities of serum GOT, GPT, Alkaline and 
phosphatase.
Curing Diseases : 
1. It is used to cure erysipelas, malaria, rheumatism, syphilis and ulcers.
2. It is used in the treatment of cardiovascular diseases and cancer. 
Research Information :
Cassia fistula fruit pulp possesses antifungal property. Secondary metabolites 
present in the extract responsible for the inhibition of fungus and its growth.
Possible Combinations : Cassia fistula + Cassia angustigolia (gall stone treatment) 
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Cassia fistula (Amaltas)VI 
            Cassia fistula is known to be native to India. For ornamental and commercial 
purpose it is extensively cultivated in Tropical region of America. Its Fruit pulp can be 
used as mild laxative, in arthritis, as well as cardiac and stomach problems. The roots 
of Cassia fistula are useful in skin diseases, tuberculous glands, syphilis and burning 
sensation. The bark is useful in boils, pustules, leprosy, ringworm, dysentery, leprosy, 
jaundice, dyspepsia, fever and diabetes. The fruit tissue has anti-inflammatory, diuretic 
and antipyretic activity. The leaves are useful in skin eruptions, eczema, ringworm and 
pruritus. It is used in the treatment of varicose veins. It helps in shrinking engorged veins 
and has a powerful anti-inflammatory effect. 
 
Major Chemical Constituents:
          The seeds are rich in glyserides and fatty acids. The bark contains lupeol, beta-
sitosterol and Hexacosanol. The fruit tissue contains substantial amount of minerals. 
 
Pharmacological Actions: 
Laxative property:  
The study was conducted to see the laxative effect of Cassia fistula. The results of 
the study concluded that Cassia fistula could be safely utilized as laxative drugs. 
Antioxidant and Anti-inflammatory activity:
Cassia fistula possesses significant Antioxidant and Anti-inflammatory activity in 
acute and chronic model of rat liver and kidney homogenates. Aqueous and alcoholic 
extract has anti-inflammatory effect in both air pouch granuloma and cotton pellet 
granuloma in male albino rat. 
Wound Healing:
Cassia fistula treated rats showed, better wound closure, improved tissue 
regeneration at the wound site, and supporting histo-pathological parameters pertaining to 
wound healing. 
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Antimicrobial:  
           The crude extract of Cassia fistula shows antimicrobial activity against various 
species of microorganisms. Ether extract of fruit pulp was found to have antibacterial 
action against both gram positive and gram-negative bacteria. 
Herb Drug interactions: 
Cassia fistula is found to have synergistic effect when it is used along with other 
laxative agents 
Safety:  
          LD50 of Cassia fistula is 6600mg/kg without any pathological effects on the organs 
examined microscopically.  
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PHYSICAL PROPERTIES 
 
 
Materials and Methods: 
The Physical properties of Sarakonraipoo Chooranam were analysed in the 
following procedure. 
pH at 10% of aqueous solution:
5gm of Sarakonraipoo Chooranam was weighed accurately and placed in clear 
100 ml beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 
minutes it was then applied in to pH mater at standard buffer solution of 4.0, 7.0, 9.2.  
Ash Values: 
The Ash values are a measure of the inorganic constituents present in the raw 
drug.  A high ash content explains its unsuitable nature to be used as a drug  
 
Total Ash: 
A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(4500C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight. 
 
Water soluble ash:
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash.  
 
Acid insoluble ash: 
     The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1). The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed.  
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BIO -CHEMICAL ANALYSIS 
  
Biochemistry lab, NIS 
.  
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Appearance of sample Brownish yellow 
in colour 
 
2. Solubility:
a. A little(500mg) of the 
sample was shaken well with 
distilled water. 
      b. A little(500mg) of the 
sample was shaken well with con. 
HCl/Con. H2So4 
 
Sparingly soluble 
 
 
Absence of 
Silicate 
3. Action of Heat: 
      A small amount(500mg) of the 
sample was taken in a dry test 
tube and heated gartly at first and 
then strong. 
 
 No white fumes 
evolved 
 
Absence of 
Carbonate 
4. Flame Test:
A small amount(500mg) of the 
sample was made into a paste with 
con. HCl in a watch glass and 
introduced into non-luminous part 
of the Bunsen flame. 
No Bluish green 
flame appeared.
Absence of 
Copper 
5. Ash Test:
A filter paper was soaked into 
a mixture of sample and dil. cobalt 
nitrate solution and introduced 
into the Bunsen flame and ignited.
Yellow colour 
flame appeared.
Presence of 
sodium 
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Preparation of Extract: 
5gm of Sarakonraipoo Chooranam was weighed accurately and placed in a 250ml 
clean beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
I.Test For Acid Radicals
1. Test For Sulphate:  
     a. 2ml of the above prepared extract was 
taken in a test tube to this added 2ml of 4% 
dil ammonium oxalate solution
     b. 2ml of the above prepared extracts was 
added with 2ml of dil-HCl was added until 
the effervescence ceases off. Then 2ml of 
dil.Barium chloride solution was added. 
No Cloudy 
appearance 
present 
 
 
 
Absence of 
Sulphate 
 
 
 
2. Test For Chloride: 
     2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate solution 
was added. 
No cloudy 
appearance. 
Absence of 
Chloride 
3. Test For Phosphate:
2ml of the extract was treated with 2ml of 
dil.ammonium molybdate solution and 2ml 
of con.HNo3. 
Yellow 
appearance 
present 
Presence of 
Phosphate 
4
.
Test For Carbonate:
2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
Absence of 
carbonate
5. Test For Nitrate:
1gm of the substance was heated with 
copper turning and concentrated H2So4 and 
viewed the test tube vertically down. 
No Brown gas 
evolved. 
Absence of
Nitrate 
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6. Test For Sulphide: 
     1gm of the substance was treated with 
2ml of con. HCL 
 
No Rotten Egg 
Smelling gas. 
 
Absence of 
Sulphide 
7. Test For Fluoride & Oxalate:
     2ml of extract was added with 2ml of 
dil. Acetic acid and 2ml dil.calcium 
chloride solution and heated. 
No Cloudy 
appearance 
Absence of 
fluoride and 
oxalate 
8. Test For Nitrite: 
     3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No 
Characteristic 
changes 
Absence of 
Nitrite 
9. Test For Borate: 
     2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
Absence of 
borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
     2ml of the extract was added with 2ml 
of dil.potassium iodine solution.
No yellow 
Precipitate 
obtained.
Absence of 
Lead 
2. Test For Copper:
One pinch(50mg) of substance was 
made into paste with con. HClin a watch 
glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate 
formed. 
Absence of 
copper 
3. Test For Aluminium:
To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess.
NoYellow 
colour 
appeared. 
Absence of 
aluminium 
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4. Test For Iron: 
     a.To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
     b.To the 2ml of extract 2ml  thiocyanate 
solution and 2ml of con HNo3 was added
 
Bloodred colour 
not appeared. 
 
Bloodred colour 
appeared. 
 
a.Absence of 
iron  
              
b.Presence of 
Iron 
5. Test For Zinc:  
     To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops to 
excess and dil.ammonium chloride was added. 
 
No White 
precipitate was  
formed 
Absence of 
Zinc 
6. Test For Calcium:  
     2ml of the extract was added with 2ml of 
4% dil.ammonium oxalate solution  
No Cloudy 
appearance and 
white precipitate 
was obtained
Absence of 
calcium
7. Test For Magnesium:  
     To 2ml of extract dil.sodium hydroxide 
solution was added in drops to excess. 
White precipitate 
was  Not 
obtained 
Absence of 
Magnesium
8. Test For Ammonium: 
     To 2ml of extract 1 ml of Nessler's reagent 
and excess of dil.sodium hydroxide solution 
are added. 
 
 No Brown 
colour appeared 
 
Absence of 
ammonium 
9. Test For Potassium:  
A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate in 
30% dil.glacial acetic acid.
 
No Yellowish 
precipitate was 
obtained. 
 
Absence of 
Potassium
10. Test For Sodium:
2 pinches(50mg) of the substance was 
made into paste by using HCl and introduced 
into the blue flame of Bunsen burner.
Yellow colour 
flame appeared 
Presence of 
sodium 
11. Test For Mercury:
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution. 
No yellow 
precipitate was 
obtained 
Absence of 
mercury 
12. Test For Arsenic:
2ml of the extract was treated with 2ml of
dil.sodium hydroxide solution.
No brownwish 
red precipitate 
was obtained 
Absence of 
arsenic 
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                                                   III. Miscellaneous 
1. Test For Starch:  
2ml of extract was treated with weak 
dil.iodine solution  
 
No blue colour 
developed 
 
Absence
of starch
2.
  
Test For Reducing Sugar: 
      5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to boil 
for 2 minutes and added 8 to 10 drops of 
the extract and again boil it for 2 minutes. 
The colour changes are noted. 
Brick red colour 
not developed 
Absence of  
reducing 
sugar 
3.
  
Test For The Alkaloids:
      a) 2ml of the extract was treated with  
2ml of dil.potassium iodide solution. 
      b) 2ml of the extract was treated with  
2ml of dil.picric acid. 
      c) 2ml of the extract was treated with 
2ml of dil.phosphotungstic acid. 
 
 
  
Yellow colour 
developed 
 
 
 
Presence  
of Alkaloid
4.
  
Test For Tannic Acid:  
      2ml of extract was treated with 2ml of 
dil.ferric chloride solution
 No black 
precipitate was 
obtained 
Absence  
of Tannic 
acid 
5. Test For Unsaturated Compound:
To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was
added.
Potassium 
permanganate 
was not 
decolourised 
Absence
of 
unsaturated 
compound
6. Test For Amino Acid:
2 drops of the extract was placed on a 
filter paper and dried well. 20ml of
Biurette reagent was added. 
Violet colour 
developed 
Presence
of amino 
acids 
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7. Test For Type Of Compound: 
      2ml of the extract was treated with 2 
ml of dil.ferric chloride solution.  
No green colour 
developed 
 
 
 
No red colour 
developed 
 
 
No violet colour 
developed 
No blue colour 
developed 
Absence of 
oxy quinole 
pinephrine 
and pyro 
catechol 
Anti pyrine,  
Aliphatic 
amino acids 
and meconic 
acid are 
absent
Apomorphin
e salicylate 
and 
Resorcinol 
are absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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THIN LAYER CHROMATOGRAPHY 
 
 
PRINCIPLE: 
Similar to other chromatographic methods TLC is also based on the principle of 
separation. The separation depends on the relative affinity of compounds towards 
stationary and mobile phase. The compounds under the influence of mobile phase (driven 
by capillary action) travel over the surface of stationary phase. During this movement the 
compounds with higher affinity to stationary phase travel slowly while the others travel 
faster. Thus separation of components in the mixture is achieved. 
Once separation occurs individual components are visualized as spots at 
respective level of travel on the plate. Their nature or character are identified by means of 
suitable detection techniques.
 
PROCEDURE:
The stationary phase is applied onto the plate uniformly and then allowed to dry 
and stabilize. But now a days ready made plates are preferred. 
A thin mark is made at the bottom of the plate with a pencil to apply the sample 
spots. Then samples solutions are applied on the spots marked on the line at equal 
distances.The mobile phase is poured into the TLC chamber to a level few centimeters 
above the chamber bottom. A filter paper moistened in mobile phase is placed on the 
inner wall of the chamber to maintain equal humidity in the entire chamber and there by 
avoid edge effect. 
Then the plate prepared with sample spotting is placed in TLC chamber such that 
the side of the plate with sample line is towards the mobile phase. Then the chamber is 
closed with a lid. 
The plate is immersed such that sample spots are well above the level of mobile 
phase but not immersed in the solvent as shown in the picture for development. 
Allow sufficient time for development of spots. Then the plates are removed and 
allowed to dry. The sample spots are visualized in suitable UV light chamber or any other 
methods as recommended for the said sample. 
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ADVANTAGES OF TLC: 
The Thin layer chromatography advantages include: 
 It is simple process with short development time. 
 It helps in visualization of separated compound spots easily. 
 The method helps to identify the individual compounds. 
 It helps in isolation of most of the compounds. 
 The separation process is faster and the selectivity for compounds is higher (even 
small differences in chemistry is enough for clear separation. 
The purity standards of the given sample can be assessed easily. 
 It is a cheaper chromatographic technique. 
 
Applications of Thin layer chromatography 
To check purity of given samples.
 Identification of compounds like acids, alcohols, proteins, alkaloids, amines, 
antibiotics etc.
 To evaluate reaction process by assessment of intermediates, reaction course etc. 
 To purify samples i.e for purification process. 
 To keep a check on the performance of other separation processes. 
 Being a semi quantitative technique, TLC chromatography is used for rapid 
qualitative measurements than for quantitative purposes. But due its rapidity of 
results, easy handling and inexpensive procedure, it finds its application as one of 
the most widely used chromatography techniques. 
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TOXICOLOGICAL STUDY 
 
ACUTE AND SUB-ACUTE TOXICITY STUDY ON SARAKONRAIPOO  
CHOORANAM IN RODENTS  
 
Animals:  
Mice of either sex weighing 25-30gm and rats weighing 210-240gm were 
obtained from the animal house of Vels University. The animals were used with the 
approval of the Institute Animal Ethics Committee and obtained from Vels University, 
Chennai. They were fed with a balanced standard pellet diet and maintained under 
standard laboratory conditions, providing 24-280C temperature, standard light cycle (12 
hr light, 12 hr dark) and water ad libitum. Animals were kept in cages with raised floors 
of wide mesh to prevent coprophagy. Animal welfare guidelines were observed during 
the maintenance period and experimentation. The rats were randomly assigned to control 
and different treatment groups, six animals per group. The animals were acclimatized for 
one week under laboratory conditions.  
 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Sarakonraipoo Chooranam was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were observed 
continuously for the first 4 hr and then each hour for the next 24 hr and at 6 hourly 
intervals for the following 48 hr after administering of the test drug, to observe any death 
or changes in general behaviour and other physiological activities. Single animals are 
dosed in sequence usually at 48 hr intervals. However, the time interval between dosing is 
determined by the onset, duration, and severity of toxic signs. Treatment of an animal at 
the next dose was delayed until one is confident of survival of the previously dosed 
animal.  
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Observation of toxicity signs:  
General behavior, respiratory pattern, cardiovascular signs, motor activities, 
reflexes, change in skin and fur, mortality and the body weight changes were monitored 
daily. The time of onset, intensity, and duration of these signs, if any, was recorded.  
 
Acute toxicity study: 
 Acute toxicity study was performed for Sarakonraipoo Chooranam according to 
the acute toxic up and down method as per OECD guidelines 425, albino mice were used 
for acute toxicity study. The animals were kept fasting for overnight providing only 
water, after which the Sarakonraipoo Chooranam was administered orally at the dose of 
1000, 2000 and 5000 mg/kg and observed for 14 days. 
 
Sub-Acute Toxicity 
 In a 28-days sub-acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while Groups II, III and IV were administered daily with the 
Sarakonraipoo Chooranam (p.o.) for 28 days at a dose of 100, 250 and 500mg/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of subacute toxicity. The weight of each rat was recorded on day 0 and 
weekly throughout the course of the study, food and water consumption per rat was 
calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the 
serum and used for the biochemical assays.
Hematological and blood biochemical analyses:
At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
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carefully collected for blood chemistry and enzyme analysis glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT) and alkaline phosphatase (ALP) 
were automatically determined using autoanalyzer.
 
Necropsy:  
All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically.
 
Statistical analysis:
Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
RESULTS AND DISCUSSION
The acute toxicity study of the Sarakonraipoo Chooranam indicated no changes in 
the behavior and in the sensory nervous system responses in the animals. Also no adverse 
gastrointestinal effects were observed in the male and female mice used in the 
experiment. All the mice that received upto 5.0g/kg dose of the Sarakonraipoo 
Chooranam survived beyond the 24 hours of observation. Hence the dose was fixed as 
100, 250 and 500mg/kg for further sub-acute toxicity study. During the sub-acute toxicity 
tests, the results obtained on the average daily water, food intake and weekly weight gain. 
The eating and drinking habit and behavior of all the animals used were normal in both 
vehicle-treated and Sarakonraipoo Chooranam treated animals. The results revealed that 
essential organs such as the liver, kidney, spleen and testes were not adversely affected 
during the sub-acute administration.
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Macroscopically, the liver, spleen, lung, testis and the kidney showed no 
discolouration and the textures were consistent when compared with the control groups. 
Histopathological examination revealed that the spleens, livers, lung, testes and the 
kidneys of rats administered with Sarakonraipoo Chooranam showed no differences 
relative to those of the control group at the two dose levels, though there was mild focal 
proximal tubular epithelial necrosis in the kidney at 500mg/kg.  
 Hence, the results indicate that Sarakonraipoo Chooranam at 500 mg/kg body 
weight is not toxic to the liver, spleen and testes of rat. There was no any significant 
changes in serum levels of cholesterol, triglycerides and protein concentration following a 
28 days treatment of the Sarakonraipoo Chooranam, it may indicate therefore, that it is 
not toxic to the animal. In conclusion, the present results show that Sarakonraipoo 
Chooranam non-toxic in rat model.  
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PHARMACOLOGICAL STUDYVII 
 
HEPATOPROTECTIVE ACTIVITY OF SARAKONRAIPOO CHOORANAM  
AGAINST CCl4 INDUCED HEPATOTOXIC RATS 
 
MATERIALS AND METHODS: 
Drugs and chemicals: 
 Silymarin was a gift sample from Micro Laboratories, Hosur, India. Aspartate 
amino transferase and Alanine amino transferase, alkaline phosphatase and total proteins 
kits were from RANDOX Laboratories Ltd. All other chemicals and reagents used were 
of analytical grade. 
 
Animals:  
Male Wistar albino rats and albino mice were used for the study. The animals 
were housed in groups of six and maintained under standard conditions (27 ± 2°C, 
relative humidity 44-56% and light and dark cycles of 10 and 14 hrs respectively), fed 
with standard rat diet and purified drinking water ad libidum one week before and during 
the experiment. All the experiments and protocols described in the present study were 
approved by the Institutional animal ethical committee  
(No: XIII/VELS/PCOL/42/2000/CPCSEA/08.08.2012).
Treatment protocol:
Group I : Normal control (normal saline) 
Group II: Hepatotoxic control (CCI4 10% v/v in olive oil) at a dose of 1ml/kg, p.o.) 
Group III:Treatment group (CCI4+Sarakonraipoo Chooranam 250mg/kg for 16 days) 
Group IV:Treatment group (CCI4+Sarakonraipoo Chooranam 500mg/kg for 16 days) 
Group V: Standard group (CCI4+Silymarin for 16 days) 
Biochemical estimation: 
At the end of the drug treatment period, all the animals were anaesthetized by 
application of light ether and blood samples were collected from a group of animals from 
retro orbital plexus. Plasma and serum samples were separated kept at 
biochemical analysis. The animals were sacrificed by deep anesthesia, the perfused liver 
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of each animal was dissected out and washed with isotonic solution, and their wet weight 
was recorded. The liver homogenate was prepared using phosphate buffer solution for 
biochemical analysis. The activities of serum aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase and total proteins were analyzed using 
commercial kits, to assess the acute hepatic damage caused by CCl4.  
 
Histopathological studies: 
 After treatment, liver of all animals from each respective groups were dissected 
fixative, dehydrated by varying percentage of ethanol and stained with haemotoxylin and 
eosin. Microscopic evaluation of the thin section was undertaken and variations in 
histoarchitecture were photographed at a magnification of 10x.  
Statistical analysis: 
The values were expressed as mean ± SEM. The statistical analysis was carried 
- test. P values 
<0.05 were considered significant. 
 
RESULTS AND DISCUSSION: 
The present studies were performed to assess the hepatoprotective activity in rats 
against carbon tetrachloride as hepatotoxin to prove its claims in traditional practice 
against liver disorders. A number of reports indicates that overdose of carbon 
tetrachloride can produce centrizonal hemorrhagic hepatic necrosis in humans and 
experimental animals. Carbon tetrachloride -induced hepatic injury is commonly used as 
an experimental method for the study of hepatoprotective effects of medicinal plants 
extracts and drugs. The extent of hepatic damage is assessed by histological evaluation 
and the level of various biochemical parameters in circulation. CCl4 undergoes hepatic 
metabolism to give rise to trichloro methyl radicals, which upon reacting with reactive 
oxygen species yields trichloromethyl peroxide radicals, which forms covalent bond with 
membrane lipids and destroy the membrane integrity It produces hepatotoxicity by 
altering liver microsomal membranes in experimental animals.
The acute toxicity study revealed the absence of lethality among the tested 
animals when the Sarakonraipoo Chooranam was administered as a single dose (1000, 
2000 and 5000mg/kg). There were no signs of any gross behavioral changes except 
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tremor indicating the safe use of the Sarakonraipoo Chooranam. The liver is known to 
play a significant role in the serum protein synthesis, being the source of plasma albumin 
and fibrinogen and also the other i -globulin. Necrosis 
or membrane damage releases the enzymes into circulation and hence it can be measured 
in the serum.  
 
 The reversal of increased serum enzymes in CCl4 induced liver damage by the 
Sarakonraipoo Chooranam may be due to the prevention of the leakage of intracellular 
enzymes by its membrane stabilizing activity. Amino transferases contribute a group of 
enzymes that catalyze th -keto acids by the transfer 
of amino groups. These are liver specific enzymes and are considered to be very sensitive 
and reliable indices for necessary hepatotoxic as well as Hepatoprotective or curative 
effect. Both AST and ALT levels increase due to toxic compounds affecting the integrity 
of the liver cells. It was evident that Sarakonraipoo Chooranam was able to reduce all the 
elevated biochemical parameters due to the hepatotoxin intoxication. 
  
The levels of total proteins and albumin were reduced due to the carbon 
tetrachloride induced hepatotoxicity. Reduction in the levels of ALP, SGOT and SGPT 
towards the normal value is an indication of regeneration process. The protein and 
albumin levels were also raised suggesting the stabilization of endoplasmic reticulum 
leading to protein synthesis. The protective effect exhibited by Sarakonraipoo Chooranam 
at dose level of 250 and 500mg/kg was comparable with the standard drug Silymarin. 
Hepatocytes of the normal group showed a normal lobular architecture of the 
liver. A comparison of the liver section of animals treated with CCl4 showed the normal 
liver architecture was disturbed by hepatotoxin intoxication characterized by cell 
vacuolation, pyknotic and degenerated nuclei and wall of bile capillaries. Sarakonraipoo 
Chooranam (250and 500 mg/kg b.w.) + CCl4, the nucleii are not very clear as in normal 
hepatocytes; however, when compared to the CCl4 damaged group, the number of 
hepatocytes with normal nucleus was much more. The endothelium is disrupted in places. 
Pyknotic nucleus and vacuolation in cytoplasm are observed to be low, as compared to 
the CCl4 group. Silymarin treated group showed normal hepatocytes and their lobular 
architecture was normal. 
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CONCLUSION: 
 The Sarakonraipoo Chooranam has shown the ability to maintain the normal 
functional status of the liver. From the above study, it can be concluded that the 
Sarakonraipoo Chooranam is proved to be one of the useful Siddha remedy for liver 
disorder.  
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DISEASE ASPECT 
SIDDHA ASPECT 
 
 
¸øÄ£Ãø §¿¡ö :
VIII 
 
§ÅÚ¦ÀÂ÷:  
 ÅÄôÀ¡ðËÃø §¿¡ö 
Á¡ó¾ì¸ðÊ
 ¸øÁ¡ó¾õ  
ÂìÌ¾õ 
ÂøÒ:  
ÅÄôÀì¸õ ¯ûª ÅÄôÀ¡ðËÃø, «ôÀì¸Óûª ¸¨¼ Å¢Ä¡ ±ÖõÒ 
Å¨ÃÂ¢Öõ ¿¢ü¸¡Áø ¾ýÉªÅ¢ø ¦ÀÕòÐì ¦¸¡ñ§¼ ÅÕÅÐõ,¾ý  Âü¨¸ 
¦¾¡Æ¢¨Ä  ÆôÀÐõ, «øÄÐ «ªÅ¢ø º¢ÚòÐì ¦¸¡ñ§¼ ÅÕÅÐÁ¡É  
Âø¨À ¯¨¼Â §¿¡ö. 
 
§¿¡ö ÅÕõ ÅÆ¢:
¯¼ü¦¸¡ùÅ¡ ¯½×¸¨ª ¯ñ½ø 
¸û, º¡Ã¡Âõ Ó¾Ä¢Â ÁÂì¸ò¨¾ ¾Õõ ÌÊÅ¨¸¸¨ª ÌÊò¾ø
¦Àñ¸ª¢ý Üð¼¡ø ÅÕõ §¿¡ö 
ÍÃ §¿¡öìÌ Ð¨½Â¡¸ ÅÕõ 
§¿¡ö ±ñ:
ÌüÈ «ªÅ¡¸ ãýÚ Å¨¸ôÀÎõ 
Åª¢ ¸øÄ£Ãø§¿¡ö 
«Æø ¸øÄ£Ãø§¿¡ö 
³Â ¸øÄ£Ãø§¿¡ö
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ÌÈ¢Ì½í¸û: 
 Á¢Ì ÍÃõ 
 Å¡ó¾¢ 
 ¾¨Ä§¿¡ö 
 «Êì¸Ê ¸Æ¢¾ø 
 º¢Ú¿£÷ º¢ÅóÐ Æ¢¾ø 
¸øÄ£Ãø ¾ýÉªÅ¢ø ¦ÀÕòÐ ¸ðÊ ÓðÊÂ¡¸ ¸¡½ø 
 ¨¾ò ¦¾¡¼÷óÐ Áïºû ¸¡Á¡¨Ä ¯ñ¼¡¾ø 
¯¼ø ¦ÅÙôÒ,Å£ì¸õ §¿¡ö¸Ùõ 
 Ð¨½§¿¡Â¡¸ ¦ÀÕÅÂ¢Úõ ÅÕõ 
¸¡Á¡¨Ä  
Ð ¸øÄ£Ãø À¡¾¢ôÀ¢É¡ø ÅÕõ §¿¡ö.
ÂøÒ:  
º¢Ú¿£÷, ¸ñ, ¿¡, ¯¼ø Â¡×õ Áïºû ¿¢Èò¨¾ô ¦ÀÚõ §¿¡Â¡õ.  
§¿¡ö ÅÕõ ÅÆ¢ : 
 ¾£ìÌüÈò¨¾ô ¦ÀÕì¸ìÜÊÂ ¦ºÂ¨ÄÔõ «ªÅ¢üÌ Å¢ïº¢Â 
¯ñ¨ÅÔõ ¦¸¡ûª¢ý, §¸¼¨¼ó¾ «ìÌüÈò¾¢ý «ªÅ¡¸ì ÌÕ¾¢ ¦¸ðÎ, 
À¢ò¾ ¿£¨Ã ÌÕ¾¢Â¢Öõ, ¯¼ø ¯ÚôÒ¸ª¡¸¢Â º¨¾, §¾¡ø, ¸ñ, ¿¡ìÌ 
ÅüÈ¢ø ¾í¸î¦ºöÐ §¿¡¨Â À¢ÈôÀ¢ìÌõ.
ÓüÌÈ¢:
"ÀÕ¸§Å ¯ûªí¸¡ Öûªí ¨¸¸û
À¸÷Ó¸í¸ñ Ï¼õÒÁ¢¸ ¦ÅÙôÒ ¸¡Ïõ 
¸Õ¸§Å ¸¡ø¨¸¸ §ª¡öºÄ¡Ìí 
¸ÉÁ¡¸ ¿Îì¸¢§Â ¨ªôÒñ¼¡Ìï 
ÍÕ¸§Å ÁÄó¾¡Ûõ ÅÈñÎ ¸ðÎõ
àÂÓ¸ Áïºª¢¼ ¿¢ÈÁ ¾¡Ìõ
¦ÅÕ¸§Å Å£ì¸Á¡ ì ¸¨ªôÒñ¼¡Ìõ
Á¢¸ì¸¡Ð Áó¾ó¾¨Ä ¸ÉôÒñ ¼¡Ìõ" 
-ä ¢¸ ÓÉ¢Å÷
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 ¦À¡Õû: 
ó§¿¡Â¢ø Å¡Â¢ø ¿£÷ °Èø, Å¡öÌÁð¼ø, ¿¡ ¨¸ò¾ø, ¯½Å¢ø 
¦ÅÚôÒ, ¯ñ½¢Ïõ ¦ºÃ¢Â¡¨Á, ¯¼ø ÅÈðº¢, §¾¡ø ÍÕí¸¢ ¾Å¨ªò §¾¡¨Ä 
´ò¾ø ±ýÛõ ÌÈ¢¸¨ªì ¸¡ðÊ ¸ñ, ¿¸ì¸ñ, Ó¸õ, ¯¼Ä¢ý §¾¡ø 
Ó¾Ä¢Â¨Å¸Ùõ, º¢Ú¿£Õõ Áïºª¢ìÌõ. «ýÈ¢Ôõ ¾¢ø ¯ûªí¸¡ø, ¨¸, Ó¸õ, 
¸ñ, ¯¼õÒ ¨Å ¦ÅÙò¾ø, ¨¸Ôõ ¸¡Öõ §º¡÷¾ø, ¯¼ø ¿Îì¸ø, «Êì¸Ê 
¨ªôÒ §¾¡ýÈø, ±Õ ¸ðÎôÀðÎ ¾£öóÐ ¦Åª¢Â¡¾ø Á¢Ìàì¸õ, ¾¨Ä 
¸Éò¾ø Ó¾Ä¢Â ÌÈ¢¸¨ªì ¸¡ðÊ ¯¼ø Ó¾Ä¢ÂÉ Áïºª¢ìÌõ §¿¡Â¡õ.
§¿¡ö ±ñ:
01. Åª¢ ¸¡Á¡¨Ä 
02. «Æø ¸¡Á¡¨Ä 
03. ³Âõ ¸¡Á¡¨Ä 
04. Åª¢ ³Âõ ¸¡Á¡¨Ä 
05. «Æ¨ÄÂõ ¸¡Á¡¨Ä 
06. ÓìÌüÈõ ¸¡Á¡¨Ä 
07. Áïºû ¸¡Á¡¨Ä 
 08. «ÆÌ ¸¡Á¡¨Ä 
09. ¦ºí¸ÁÄ ¸¡Á¡¨Ä 
10. ÌõÀ ¸¡Á¡¨Ä 
11. ÌýÁ ¸¡Á¡¨Ä 
12. °Ð ¸¡Á¡¨Ä 
13. ÅÈû ¸¡Á¡¨Ä
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MODERN ASPECTIX 
 
Jaundice, also known as Icterus, is a term used to describe a yellowish tinge to 
the skin and sclerae (the white part of the eye) that is caused by hyperbilirubinemia (an 
excess of bilirubin in the blood). Body fluids may also be yellow. The color of the skin 
and sclerae varies depending on levels of bilirubin, mildly elevated levels display yellow 
skin and sclerae, while highly elevated levels display brown 
Bilirubin (bil-ih-ROO-bin) is a yellow colored substance that is responsible for the 
yellowing of the skin and sclerae. Bilirubin is a waste product that remains in the 
bloodstream after the iron is removed from the hemoglobin, which is released from the 
degradation of erythrocytes (cells that contain hemoglobin and can carry oxygen to the 
body). When there is an excess of bilirubin it may leak out into surrounding tissues, 
saturating them with this yellow substance.  
Bilirubin that is circulating freely in the blood is called unconjugated bilirubin. 
One of the liver's functions is to filter out waste, such as bilirubin, from the blood. Once it 
is in the liver, other chemicals latch on to the bilirubin, creating a substance called 
conjugated bilirubin, which is secreted in bile (a digestive juice released by the liver) and 
then excreted. Bilirubin is what gives feces its brown color.  
The modern English word jaundice is derived from the middle French word 
jaunisse. Jaun 
jaunisse
A yellowish staining of the integument, sclerae, deeper tissues and excretions with bile 
pigments, resulting from increased levels in the plasma
There are 3 main types of jaundice:
Hepatocellular jaundice
Hemolytic jaundice
Obstructive jaundice
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Hepatocellular jaundice:  
A type of jaundice that occurs as a result of liver disease or injury.  
Hemolytic jaundice:  
A type of jaundice that occurs as a result of hemolysis (an accelerated breakdown 
of erythrocytes - red blood cells) leading to an increase in production of bilirubin.
Obstructive jaundice:
A type of jaundice that occurs as a result of an obstruction in the bile duct (a 
system of tubes that carries bile from the liver to the gallbladder and small intestine), 
which prevents bilirubin from leaving the liver.  
Jaundice, not to be confused with infant jaundice, is usually a sign of an 
underlying disorder.  
 
Causes:  
Jaundice most often occurs as a result of an underlying disorder that either causes 
tissues to become over-saturated with bilirubin or prevents the liver from disposing of 
bilirubin. Some underlying conditions that may cause jaundice are: 
Acute inflammation of the liver:
May impair the ability of the liver to conjugate and secrete bilirubin, 
resulting in a buildup of bilirubin.
Inflammation of the bile duct:
May prevent the secretion of bile and removal of bilirubin, causing 
jaundice.
Obstruction of the bile duct:
Prevents the liver from disposing of bilirubin, which results in 
hyperbilirubinemia.
Hemolytic anemia:
Production of bilirubin increases when large quantities of erythrocytes are 
broken down. 
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 Gilbert's syndrome:  
An inherited condition that impairs the ability of enzymes (biomolecules 
that provoke chemical reactions between substances) to process the excretion of 
bile.  
 Cholestasis:  
A condition in which the flow of bile from the liver is interrupted. The bile 
containing conjugated bilirubin remains in the liver instead of being excreted.  
More rare conditions that may cause jaundice include :
 Crigler-Najjar syndrome:  
An inherited condition that impairs the specific enzyme responsible for 
processing bilirubin, resulting in an excess of bilirubin.
 Dubin-Johnson syndrome:  
An inherited form of chronic jaundice that prevents conjugated bilirubin 
from being secreted out of the liver's cells. 
 Pseudojaundice:  
A harmless form of jaundice in which the yellowing of the skin results 
from an excess of -carotene not from an excess of bilirubin; usually from eating 
lots of carrots, pumpkin, or melon.  
 
Signs and symptoms: 
The most pervasive sign of jaundice is a yellow tinge to the skin and sclerae 
(whites of the eyes). This usually starts at the head and spreads down the body.
Other symptoms of jaundice include:
Pruritis (itchiness)
Fatigue
Abdominal pain - typically indicates a blockage of the bile duct.
Weight loss
Vomiting
Fever
Paler than usual stools
Dark urine 
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Complications: 
The symptom pruritis (itching) can sometimes be so intense that patients scratch 
their skin raw, have insomnia or even commit suicide.  
Most complications that arise are a result of the underlying cause of jaundice, not 
from jaundice itself. For example, jaundice caused by a bile duct obstruction may lead to 
uncontrolled bleeding due to a deficiency of vitamins needed for normal blood clotting.  
 
Prevention:  
Jaundice is related to the function of the liver, so it is essential that you maintain 
this vital organ's health by eating a balanced diet, exercising at least 30 minutes five times 
a week, and refraining from exceeding recommended amounts of alcohol.
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CLINICAL STUDY 
 
The pilot study on patients with Kamalai (Liver disease), and satisfying the 
inclusion criteria was conducted at the OPD, Ayothidoss Pandithar Hospital, National 
Institute of Siddha, Chennai-47. 
 
Sample size:  
20 patients. 
SUBJECT SELECTION:
Inclusion Criteria:
 Age   : 30-60 years  
 Sex   : Both male and female  
 Weight : 35-80 kg  
 Patient having symptoms of, 
Malaise 
Anorexia 
Nausea
Vomiting 
Jaundice 
Upper abdominal pain
(Any of the 4 or 5 clinical symptoms) 
Patient who are willing to provide blood sample for lab investigation.
Patient who are willing to attend OPD once in 7 days.
Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 30 days but can opt out of the trial of his/her 
own conscious discretion.
Exclusion Criteria:
A known case of any obstructive liver disease
Cardiac disease 
Hepatic failure 
Pregnancy and lactation 
Any other serious illness
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Withdrawal Criteria: 
 Development of any adverse reaction  
 Occurrence of any other serious illness 
 Non co-operation of the patient 
 
Trial Drug And Duration  
Drug:     
  Sarakonraipoo Chooranam-1gm, bid with milk. 
Duration of the study:  
  30days 
 
Conduct of the study:
Kamalai (Liver disease) patients satisfying inclusion and exclusion criteria were 
attend to the trial. Informed consent was obtained from the patients. Routine 
investigations like Blood test, urine test, and PEFR were carried out before and after the 
trial treatment. For out patients the trial drug was issued for 7 days course. They were 
advised to visit the OPD once in 7 days. At each visit they were clinically assessed.  
 
Clinical observation: 
Sarakonraipoo (Liver disease), 
20 patients were selected.
Among 20 patients, 16 (80 
According to age wise distribution 50% were in 30-40 years, 35% were in 41-50 
years and 15% were in 51-60 years. 
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DISCUSSION 
 
  
The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to evaluate the therapeutic efficacy of the drug Sarakonraipoo chooranam in the 
management of  Kamalai (Liver disease). 
 As per Siddha text in Kamalai, pitha humors were deranged and also with kabam 
humors.  
Pitha thathu has the basic function of production and maintenance of the blood 
environment and also for appetite and proper digestion of foods. Hence Pitha thathu when 
deranged produces symptoms like nausea, vomiting. 
 The trial drug Sarakonraipoo chooranam possess thuvarppu suvai and kaarppu 
veeryam, hence it balances the deranged pitham and kaba kutram. 
Hence administration of the trial drug Sarakonraipoo chooranam was effective in 
the management of Kamalai. 
 The trial drug was studied as per OECD guidelines.  
 The preliminary phytochemicals screening of the trial drug Sarakonraipoo 
chooranam was done by using GC-MS.  The result shows the presence of Alkaloid, 
Flavanoid, Glycosides, Amino acids, and Triterpenoids.
Bio-chemical analysis of the trial drug was done and it shows the presence of 
sodium, phosphate, alkaloids, amino acids, iron. 
 
Toxicity Study 
The pre-clinical study result ensures the safety and efficacy of the drug. 
The results indicate that Sarakonraipoo Chooranam at 500 mg/kg body weight is 
not toxic to the liver, spleen and testes of rat.  
There was no any significant changes in serum levels of cholesterol, triglycerides 
and protein concentration following a 28 days treatment of the Sarakonraipoo 
Chooranam, it may indicate therefore, that it is not toxic to the animal. 
In conclusion, the present results show that Sarakonraipoo Chooranam non-toxic 
in rat model.  
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Pharmacological Study  
The Sarakonraipoo Chooranam has shown the ability to maintain the normal 
functional status of the liver. From the above study, it can be concluded that the 
Sarakonraipoo Chooranam is proved to be one of the useful Siddha remedy for liver 
disorder.  
 
Clinical Observation:  
Age:  
 Among the 20 patient 50% of them were in the age group of 30-40. It reveals that 
mostly young and middle age group peoples were affected.  
Sex:
All patients included were both Male and Female.  
Gunam and Diet: 
All patients included in this study were having Thamo Gunam and they have non-
vegetarian diet regularly.  
 
Body constitution: 
All patients were observed to have Thondha Udal type of body constitution. 
Thinai 
In this study 75% of the patients were from Mullai Thinai and remaining 25% of 
people were from Kurinji Thinai. People from Mullai Thinai have more chances to 
develop deranged Pitham humor. 
Family history 
Among 20 patients 35% of the patients show positive family history. 
Occupational history 
Occupational history of the patients showing that, 
55% of patients were coolies 
35% of patients were farmers and 
10% of patients were others.
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Socio-economic status 
Among 20 patients , 55% of patients were poor and 35% of them were from lower 
middle class. 
In low-income countries such as India the prevalence of alcohol and tobacco use 
is higher among the poor, which increases the risk of cardiovascular disease, cancer, liver 
disease and injuries. 
 
Naadi 
Among 20 patients 65% were having pithakaba naadi and 35% of them having 
kabapitha naadi. This shows that in Kamalai both pitham and kaba humors were 
deranged. 
 
Clinical symptoms
Among 20 patients,  
 85% of patients relieved from malaise.  
It may be because of presence of amino acid  in the trial drug.  
 75% of patients relieved from anorexia.  
 70% of patients relieved from nausea 
85% of patients relieved from vomiting 
80% of patients relieved from upper abdominal pain. 
Investigations 
Among 20 patients the serum enzyme markers
Total bilirubin, Direct bilirubin and Indirect bilirubin level was significantly 
reduced in 75% of patients 
SGOT, SGPT and Serum Alkaline phosphatase level was significantly reduced in 
75% of patients. 
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SUMMARY  
 
 The drug Sarakonraipoo chooranam was selected to evaluate the Hepato-
protective activity in the management of Kamalai (Liver disease). 
 The qualitative and quantitative analyses were carried out at Biochemistry lab, 
NIS and IITM, Chennai respectively. The results ensure the Hepato-protective 
activity of the Sarakonraipoo chooranam was due to the presence of active 
phytoconstituents of the drug. 
 The pre-clinical evaluation (acute & repeated oral toxicity study) of the drug was 
carried out as per OECD guidelines in Vels University, Chennai. The result shows 
safety of the trial drug for human administration. 
The Preclinical and Pharmacological study was carried out in in Vels University, 
Pallavaram, Chennai. The result shows that the drug has significant Hepato-
protective effect. 
 As per Siddha literature, Modern science reviews and Research articles the trial 
drug has potent Hepato-Protective effect. 
 20 Patients were recruited for clinical trial.  The trial drug Sarakonraipoo 
Chooranam at the dose of 1gm, bid was given to the patient for 7 days and 
patients were asked to visit the OPD once in 7 days for 30 days. Clinical 
assessment and prognosis was noted at each visit.
At the end of clinical trial the results showed that,
85% of patients relieved from malaise, 75% of patients relieved from 
anorexia, 70% of patients relieved from nausea, 85% of patients relieved from 
vomiting and 80% of patients relieved from upper abdominal pain and no 
noticeable adverse effects were observed during trial period.
The blood investigation also shows significant results. There is marked 
reduction in serum enzyme markers, 75% of patients have reduction in Total 
Bilirubin, Direct bilirubin and Indirect bilirubin. 70% of patients have reduction in 
SGOT, SGPT and Serum Alkaline phosphatase. No adverse effects were reported 
during the treatment period.
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CONCLUSION
 
 
 The literature and research journal review of the plant shows that it has got 
significant Hepato-protective activity. 
 The safety studies (acute and repeated oral toxicity) studies conducted revealed 
that the trial drug Sarakonraipoo Chooranam is safe. There were no abnormalities 
found in blood investigation and histo-pathological examination. Hence it can be 
reasonably assumed that the drug is safe for human use. 
 The pharmacological study conducted in animal model shows significant Hepato-
protective activity. 
Clinical study revealed the therapeutic efficacy of the trial drug by showing, 
reduction in serum enzyme markers Serum Total bilirubin, Direct bilirubin, 
Indirect bilirubin, SGOT, SGPT and Serum Alkaline phosphatase levels 
significantly. There was improvement in other clinical symptoms before and after 
treatment. 
 There were no adverse reactions complained during the clinical trial. 
 Hence, the drug Sarakonraipoo Chooranam can be used in the management of 
Kamalai (Liver disease).  
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INTRODUCTION 
  
Siddha system is considered to be one of the ancient system of medicine in the 
world. Siddha is a complete holistic medical system that has been practiced in India for 
two thousands of years above.  
 
The siddha system of medicine has derived its name from the word "Siddhi", 
which means "Perfection" or "Eternal bliss". Siddhi refers to the eight supernatural 
powers that are attainable by man. Those who attained these supernatural or perfection or 
Siddhi were called  "Siddhars". They realised that if the body could be made strong and 
perfect, they could get rid of death and diseases. 
 
They have fully investigated and studied the cause and the effects of 
the diseases and all kinds of drugs, minerals and poisons. They imparted  
their knowledge for the upliftment of the suffering community. 
 
Panchapootha theory has also been described by Siddhars. The panchapoothas are 
Akasam or veli (ether), Kaattru or vayu (air), Thee or agni  (fire), Neer or appu (water), 
Nilam or piruthuvi (earth).  
 
Every form of matter has to be considered as panchapoothas in its orgin Vali 
( ) Azhal ( ) Iyam  ( ) are the three main Physiological regulators of the body 
and mind. They are called "Muththathukkal". They remain always in a state of equipoise 
in healthy individuals. Increase or decrease of one or more will cause disease.
§À¡üÈ¢ .
X
Generally when a medicine is administrated Siddha Physician prescribes diet 
regimen according to the nature of the medicine and severity of the disease. This is 
because over intake or consuming unbalanced and incompatible diet is considered to be 
the prime causative factor for upsetting the tridhosa balance leading to manifestations of 
various ailments.
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Madhumegam is also called as "Neerizhivu" characterised by increased and 
frequent passing of urine, which is sweet in odour, resulting in gradual diminition of 
udalthathus.  
 
Siddhars also described that 20 types of pramegam  according to tridhoshas and 
are described on the basis of colour, consistency, taste, smell, weight, sedimentation etc. 
  
The evidence or proof for this disease has been described by "Yugi Munivar" in 
his text "Vaidhya Chinthamani 800". Four varieties under vatham, Six due to pitham, and 
ten due to kabam. One among in Pitha is called Madhu megam. 
 
The signs and symptoms of  "madhumegam" in siddha text may be  correlated 
with that of "Diabetes mellitus" in modern science. 
 
Accorging to Yugimuni & Agasthiar this disease is due to Kanma or Karmam that 
is hereditary, also due to dietetic variations. According to "Nadi Nool" it is said to be due 
to over indulgence in sex. Pittha thadhu is highly accountable for the maintenance of life 
process, with proper treatment the severity of the disease can be controlled by potent 
drugs with diet regimen and yoga. 
Diabetes mellitus is a clinical syndrome charecterised by hyperglycemia caused 
by absolute or relative deficiency of Insulin.XI
It has 3 types 1.Type I
2.Type-II 
3.Gestational type. 
Type 2 diabetes is a more complex condition than Type 1 diabetes because there is 
a combination of resistance to the actions of insulin in Liver and muscle together with 
-
According to the World Health Organization In 2000 B.C the age group of 20-44 
years have been affected in 35 millions of world population. It is increased to 58 million 
in this age group at 2030 A.D 
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Age group: 45-64 years,  In 2000 A.D.--------- 82millions  
    In 2030 A.D.---------174 millions  
Age group: 65+ years,  In 2000 A.D.----------56 millions  
    In 2030 A.D.---------130 millions  
  
The increase in incidence of diabetes in developing countries follows the trend of 
urbanization and lifestyle changes, perhaps most importantly a "Western-style" diet.  
 
India: The Diabetic Capital of The World: 
The International Diabetes Federation recently published findings revealing that in 
2007, the country with the largest numbers of people with diabetes is India (40.9 million), 
followed by China (39.8 million), the United States (19.2 million), Russia (9.6 million) 
and Germany (7.4 million).XII    
  
The modern clinical entity "Diabetes Mellitus" resembles one of the  
variety of pittha prameham ie. "Madhumegam" very closely. The former being a 
metabolic disorder caused by insufficient insulin action or its deficiency characterised by 
raised blood sugar level, the chief clinical features are polyuria, polyphagia, polydipsia,
ketonuria, hypokalemia, cellular dehydration etc.  The author is very obliged to do this 
work and to prepare some facts in this disease and principles involved in the care of this 
disease.
The formulation, "Kandha Chenduram" is indicated for Madhumegam in Siddha 
text "Kannusamy Parambarai Vaithiyam".
Hence the author has selected the medicine "Kandha Chenduram" for 
Hypoglycemic Activity in the management of Madhumegam (T2 Diabetes Mellitus).
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AIM AND OBJECTIVE 
 
AIM 
Activity in the management of  Madhumegam [Diabetes Mellitus]. 
 
OBJECTIVE 
PRIMARY OBJECTIVE: 
studies. 
 
SECONDARY OBJECTIVE: 
Biochemical analysis: 
 
in the management of Madhumegam [Diabetes Mellitus].  
 
Collections of evidences in siddha literature 
 
Collection of evidences in mineralogical  aspects 
ICPOES
Toxicological Study: 
Acute toxicity
Su- acute toxicity 
Pharmacological Study: 
Hypoglycemic activity
Clinical study:
Pilot study on trial drug 
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MATERIALS AND METHODS: 
 
 
STANDARD OPERATIVE PROCEDURE:  
Collection and Authentication of the raw drugs: 
The drug was procured from Ramasamy Chetty shop Paris, Chennai and 
authenticated by competent authority in, the Head of department Gunapadam. 
 
Ingredients:XII 
 Purified Kandham (magnetic oxide ofiron)  
 Manjal(Potrilai)Kaiyanthakarai charu(wedelia chinensis),  
 Sotrukatrazhai charu (aloe vera),  
Navalpattaicharu (bark of Syzygium cumini),  
Arasampattaicharu (bark of Ficus religiosa),  
Ezhumichampazhamcharu (Citrus limon)   
 
Purification process:  
Purification of Kandham: 
 Blow the 2-3 palams of  Kandham (Magnetic Oxide of Iron) by using the blower,  
repeated for 7 times.
Preparation of the medicine:
The purified Kandham was made into a fine powder by the Kalvam. Then the 
Kandham was grinded by the juice of wedelia chinensis little by little for 9,12 hours (3,4 
samam) and made in to villai. The villai was dried and placed in a Mudpot covered by 
another Mudpot with clay pasted cloth. Then it was made for Pudam with 20-25 cow 
dung cake, after the heat was decreased in the Pudam. It was taken and the same repeated 
with wedelia chinensis juice. The same procedure was repeated with Aloe vera juice, 
Syzygium cumini juice, Ficus religiosa juice, Citrus lemon juice and made for Pudam 
twice for each other juices. Then the chenduram is collected in a clean, air tight glass 
container.
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LABELLING:  
Name of the preparation : Kandha Chenduram  
Color     : Reddish orange 
Quantity of the drug  : 2 gm 
Dose     : 130 mg, bid 
Adjuvant/ vehicle   : Ghee 
Indication    : Madhumegam [Diabetes Mellitus].  
Date of manufacturing : 14/07/2012 
Date of expiry   : 75 years from the date of manufacture  
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REVIEW OF LITERATURE 
  
 
¸¡ó¾õ - MAGNETIC OXIDE OF IRONXIV 
 
§ÅÚ ¦ÀÂ÷ :
º¢Å§Ä¡¸î §ºÅ¸ý
¾Ã½¢ìÌ ¿¡¾õ 
Ý¾ «íÌºõ 
¿Å§Ä¡¸ò ÐÃðÊ
¸¡Âº¢ò¾¢ìÌ À¡ò¾¢ÃÅ¡ý
ÓÕ¸ý ÒÃ¡½õ
¦À¡ÐìÌ½õ:  
  ¸¡ó¾ò¾¡ü §º¡¨ÀÌýÁí ¸¡Á¢Ä§Á ¸õÀ¡ñÎ  
  §º÷ó¾¾¢Ã¢ §¾¡¼¦Åð¨¼ º£¾í¸¡ø - µöó¾Àº¢  
  §ÀÕ¾Ãí ¸ñ§½¡ö À¢ÃÁ¢Â¿£ Ã¡¨ÁÔõ§À¡õ  
µÃ¢É¢¨È Â¡ÔÙÚõ ¯ý.
¦À¡Æ¢ôÒ¨Ã:
¸¡ó¾ì¸ø Å£ì¸õ, ÌýÁõ, ¸¡Á¡¨Ä, §Á¸õ , À¡ñÎ, Óò§¾¡¼õ,¦Åû¨ª 
Å£Æø, º£¾ªõ, Å¡¾§¿¡ö, Áó¾õ, Á§¸¡¾Ãõ, Å¢Æ¢§¿¡ö, À¢ÃÁ¢Âõ, ¿£Ã¡¨Áì¸ðÊ 
Ó¾Ä¢Â §¿¡ö¸û ¿£íÌõ. âÃ½ ¬ÔÙõ ¯ñ¼¡õ.
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Áïºû ¸ Ã¢º¡¨Ä - Wedelia chinensisXV 
 
§ÅÚ¦ÀÂ÷:   
¦À¡üÈ¨Äì ¨¸Â¡ó¾¸¨Ã,  
  Áïºû ¨¸Â¡ó¾¸¨Ã  
 
ÀÂýÀÎõ ¯ÚôÒ: âñÎ  
Í¨Å   : ¨¸ôÒ  
  ¾ý¨Á  : ¦ÅôÀõ  
  À¢Ã¢×   : ¸¡÷ôÒ  
 
¦ºö¨¸:  
À¢ò¾ ¿£÷ô¦ÀÕì¸¢  À¢ò¾¸¡Ã¢   Cholagogue 
¯ÃÁ¡ì¸¢   ÀÄ¸¡Ã¢   Tonic  
  ¯¼ü§ÈüÈ¢    ùÂ¾§¼¾¸¡Ã¢  Alterative   
  Å¡ó¾¢Ôñ¼¡ì¸¢   ÅÁÉ¸¡Ã¢  Emet  
  ¿£÷ÁÄõ§À¡ì¸¢   ù§ÃºÉ¢   Purgative  
  Å£ì¸ÓÕì¸¢   §º¡À¡¿¡º¢É¢  Deobstruent  
®Ãø§¾üÈ¢ Â¸¢Õ¾ÀÄ¸¡Ã¢ Hepatotonic
Classification:
Kingdom : Plantae
Clade : Angiosperms
Class : Dicots
Sub-class : Gamopetalae 
Series : Inferae
Order : Asterales 
Family : Asteraceae
Genus : Wedelia
Species : W.chinensis
Botanical name : Wedelia chinensis
50 
Chemical constituent:XVI  
 Ecliptine present in leaves.  
Pharmacological activity:  
 It is an interesting source of potential bioactive molecules, as iridoids compounds, 
flavonoids, diterpenoids derivatives, phytosteroids, with antioxidant, anti-inflammatory, 
antimicrobial, Hepatoprotective activity, analgesic and antihistamine, Anti-implantation, 
antiasthmatic activities and anticancer activity.  
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§º¡üÚì ¸üÈ¡¨Æ
XVII
 - Aloe vera, mill 
 
§ÅÚ ¦ÀÂ÷ :  
¸ýÉ¢  
ÌÁÃ¢  
 
À¢È¦Á¡Æ¢¸û:    
  English  : Indian Aloes, Curacao aloe  
  Telugu  : Kalapanda  
  Malayalam : Kattuvazha  
  Kannada  : Kathalai gidsa, lolisara  
  Sanskrit  : Kumari  
  Hindi   : Ghikauvar  
 
ÀÂýÀÎõ ¯ÚôÒ: º¡Ú   
      
Í¨Å   : º¢Ú¨¸ôÒ  
¾ý¨Á : ¾ðÀõ
  À¢Ã¢×   : É¢ôÒ  
¦ºö¨¸:
¯ÃÁ¡ì¸¢ ÀÄ¸¡Ã¢ Tonic
¯¼ü§¾üÈ¢ Å¢Â¡¾¡§À¾¸¡Ã¢ Alterative
¿£÷ÁÄõ§À¡ì¸¢ Å¢§Ãº¢É¢ Purgative
ÕÐ ¯ñ¼¡ì¸¢ ÕÐÅ÷ò¾¢É¢ Emmenagogue
¦À¡ÐÌ½õ:
¦À¡øÄ¡§Á ¸í¸ÀõÒ ØîÝ¨Ä Ìð¼Ãºõ
«øÄ¡÷Áò ¾õÀ¸ó¾ ÃíÌýÁõ ±øÄ¡õÅ¢ð
§¼Ì ÁÃ¢ìÌ ¦ÁÃ¢îºü ¸¢Ã¢îºÃÓ
Á¡Ì ÁÃ¢ìÌ ÁÕñÎ.
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¦À¡Æ¢ôÒ¨Ã:  
 ÌÁÃ¢Â¡ø Å¡¾§Á¸õ , ¸Õ§Á¸õ, ¸¢ÕÁ¢ìÌò¾ø, ¦ÀÕÅ¢Â¡¾¢, ãÄõ, 
¯ýÁ¡¾õ, À¸ó¾Ãõ, ÌýÁõ, À¢ò¾¸¢Ã¢îºÃõ ¨Å §À¡õ.  
 
Classification:  
  Kingdom   : Plantae  
  Clade    : Angiosperms  
  Class    : Monocots 
Order : Asparagales
  Family     : Xanthorrhoeaceae  
  Subfamily  : Asphodeloideae  
  Genus    : Aloe  
Species : A.vera 
Botanical name  : Aloe vera, mill 
 
Pharmacology activity:XVIII  
 Anti-inflammatory, anti-bacterial, anti-viral, anti-oxidant and energy tonic 
 
Uses:XIX 
There is preliminary evidence that Aloe vera extracts may be useful in the 
treatment of diabetes.
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¿¡ÅøXX - Syzygium cumini. Linn 
 
§ÅÚ¦ÀÂ÷:  
¿ùÅø  
  ¿õÒ 
  ºõÒ  
  º¡¾Åõ  
  ¬Õ¸¾õ  
  §¿§ÃÎ 
  §¿§Ã¼õ  
  º¡ðÎÅÄõ  
  º¡õÀø 
  ÍÃÀ¢Àò¾¢¨Ã 
 
À¢È¦Á¡Æ¢¸û:  
English   : Jambul  
  Telugu   : Neradu  
Malayalam : Gnaval
  Kannada   : Neralu  
Sanskrit : Jambu
Hindi : Jamuns
Duk : Jamoon
ÀÂýÀÎõ ¯ÚôÒ: ±øÄ¡ô ¦À¡ÕÙõ (Àð¨¼) 
Àð¨¼ : Í¨Å : ÐÅ÷ôÒ
¾ý¨Á : ¾ðÀõ
À¢Ã¢× : ¸¡÷ôÒ
¦ºö¨¸: ÐÅ÷ôÀ¢ Astringent
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¦À¡ÐÌ½õ:  
  Á¡ó¾õ Å¢¨ªÔõ ÅÄ¢¸ÃôÀ¡ Ûñ¼¡Ìõ  
  §º÷ó¾¦¾¡Õ ¿£Ã¢Æ¢×ï §ºÕ§Á¡ - ¿¡ó¾¦Ä¡Î  
  Å¡ö×í ¸ÎôÒõ ÅÕí¦¸¡¾¢ôÒó ¾¡¸Óõ¦À¡õ  
  àÂ¿¡ ÅüÀÆò¾¡ø ¦º¡ø.XXI  
           
¦À¡Æ¢ôÒ¨Ã:
¿¡ÅüÀð¨¼Â¡ø ¸ÎÅý, ¸ÃôÀ¡ý, Á¡ó¾õ ¨Å ¯ñ¼¡õ. ¿£Ã¢Æ¢×, 
¦ÅôÀõ, Å¡Ô, ¸ÎôÒ, ¿£÷§Åð¨¸ ¨Å¸û ¿£íÌõ.
Classification:  
  Kingdom   : Plantae  
  Clade    : Angiosperms  
  Class    : Monocots 
  Seris    : Calyciflorae  
Order    : Myrtales   
  Family     : Myrtaceae   
  Genus    : Syzygium  
  Species   : S.cumini  
Botanical name : Syzygium cumini, Linn
Pharmacological study:XXII 
Tea, extracts, solutions, and other preparations from plants with a putative 
antihyperglycemic effect have a worldwide utilization in the treatment of diabetes (1). 
Among them, the tea prepared from leaves of jambolan [Syzygium jambos (L.) Alst 
or Syzyguium cumini (L.) Skeels] is largely used in our city (2) and elsewhere (3). We 
demonstrated that the tea and extracts from different parts of the plant had no effect in 
normal rats (4), rats with streptozotocin-induced diabetes (5), and normal volunteers (6). 
An antihyperglycemic effect in patients with diabetes, however, could not be ruled out, 
since its mechanism of action could depend on specific abnormalities of diabetes in 
humans. 
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In this double-blind, double-dummy clinical trial, we randomized patients with 
type 2 diabetes to receive a tea prepared from leaves of Syzygium cumini (two grams per 
liter of water, taken as water substitute) plus placebo tablets, placebo tea (prepared with 
dried leaves of Imperata braziliensis Trinius) plus glyburide tablets (5 mg twice a day), or 
placebo tea plus placebo tablets. 
Fasting blood glucose levels decreased significantly in participants treated with 
glyburide and did not change in those treated with the Syzygium cumini tea and in the 
-glutamyl 
transferase, alkaline phosfatase, SGOT, SGPT, 24-h glicosuria, 24-h proteinuria, 
triglycerides, and total, LDL, and HDL cholesterol did not vary significantly among the 
groups. 
With this clinical trial, we have completed a cycle of experiments showing that the 
tea and extracts prepared from leaves of Syzygium cumini are pharmacologically inert. 
Patients and physicians should not rely on the putative antihyperglycemic effect of this 
tea, and perhaps of other folk medicines, that pretend to have such an effect. The 
investigation of plants with potential clinical utility could start with a clinical trial testing 
the effect of folk preparations in order to isolate the active principles of those products 
that show pharmacological activity in this model.  
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«ÃÍ
XXIII
 - Ficus religiosa. Linn. 
 
§ÅÚ¦ÀÂ÷:  
 
  «îÍÅò¾õ  
  ¾¢ÕÁÃõ 
¸Å¨Ä
§À¾¢
À¨½
¸½Åõ
ºÃ¡ºÉõ
À¢ôÀ¢Äõ 
À¢È¦Á¡Æ¢¸û: 
English  : The peepul tree; Sacred fig  
  Telugu  : Ravichettu  
  Malayalam  : Areyal, arasu  
  Kannada  : Aswathamaram, Pimpala  
Sanskrit : Aswadtha
Urudu : Peepul paras
Hindi : Pipol
Duk : Anipeepul
ÀÂýÀÎõ ¯ÚôÒ : ¨Ä, Å¢òÐ, Àð¨¼, §Å÷
Àð¨¼ : Í¨Å : ÐÅ÷ôÒ
¾ý¨Á : ¾ðÀõ
À¢Ã¢× : É¢ôÒ
¦ºö¨¸:
ÐÅ÷ôÀ¢ Astringent
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Classification:  
Kingdom   : Plantae 
  Clade    : Angiosperms  
  Class    : Dicots  
  Sub-class   : Monochlamydeae  
  Seris    : Unisexuales   
  Family     : Urticaceae  
  Sub-family   : Moraceae  
  Genus    : Ficus  
  Species   : F.religiosa  
Botanical name  : Ficus religiosa, linn  
 
Pharmacological activity:XXIV  
 Andtidiabetic activity, Analgesic activity, Anti-inflammatory activity, Anti-
oxidant Activity, anti convulsant, Anti microbial Activity, wound healing, Anti-amnesic 
activity, Anti-acetylcholinesterase Activity, Proteolytic Activity. 
 
Antidiabetic activity:  
Aqueous extract of F.religiosa in a dose of 50 and 100mg/kg shows
pronounced reduction in blood glucose levels in normal, glucose-loaded hyperglycemic 
and streptozotocin (STZ) induced diabetic rats and effect was compared with 
glybenclamidea well known hypoglycemic drug. Aqueous extract of F.religiosa showed 
significant increase in serum insulin, body weight, glycogen content in liver and skeletal 
muscle of STZ-induced diabetic rats, also reduced the serum triglyceride and total 
cholesterol level. The result suggested potential traditional use of F. religiosa. Ambike et 
al investigated that a phytosterolin isolated from F. religiosa root bark when given at a 
dose of 25mg/kg orally to fasting rabbits produced maximum fall of the blood sugar level, 
equivalent to 81% of the tolbutamide standard, after 4 hrs, while with i.v. injections of 5-
7.5 mg/kg a maximum effect was achieved after 2 hr.
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±ÖÁ¢îºõÀÆõ
XXV
 - Citrus limon (Linn) Burm.f. 
 
§ÅÚ¦ÀÂ÷:  
ºõÀ£Ãõ  
  º¾¡ÀÄì¸É¢  
 
ÀÂýÀÎõ ¯ÚôÒ: ¨Ä, ¸¡ö, ÀÆõ, ÀÆÃºõ, ±ñ¦½ö.  
ÀÆõ:  Í¨Å   : Òª¢ôÒ  
  ¾ý¨Á  : ¦ÅôÀõ  
  À¢Ã¢×   : ¸¡÷ôÒ  
¦ºö¨¸:   
Ìª¢÷îº¢Ôñ¼¡ì¸¢   º£¾ª¸¡Ã¢   Refrigerant
 
¦À¡ÐÌ½õ:   
¾¡¸õ Ì¿¸§¿¡ö ¾¡Æ¡î º¢Ä¢À¾§¿¡ö 
  §Å¸í¦¸¡û ¯ýÁ¡¾õ Å£ÚÀ¢ò¾õ - Á¡¸ñ§½¡ö  
  ¸ýÉ§É¡ö Å¡ó¾¢Ôõ§À¡í ¸ðÎÅ¡ ¾¢ò¦¾¡Æ¢Ä¢ø  
Áý¦ÉÖÁ¢î ºí¸É¢¨Â Å¡úòÐ.
Classification: 
Kingdom : Plantae 
Clade : Angiosperms
Class : Dicots
Sub-class : Polypetalae
Seris : Disciflorae
Order : Geraniales
Family : Rutaceae
Genus : Citrus
Species : C.limon 
Botanical name : Citrus limon (Linn) Burm.f.
Pharmacological activity:XXVI
Hypoglycemic activity 
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PHYSICAL PROPERTIES 
 
Materials and Methods 
The Physical properties of Kandha Chenduram were analysed in the following 
procedure. 
 
pH at 10% of aqueous solution:
5gm of Kandha Chenduram was weighed accurately and placed in clear 100 ml 
beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 minutes 
it was then applied in to pH mater at standard buffer solution of 4.0,7.0,9.2.  
Ash Values 
The Ash values are a measure of the inorganic constituents present in the raw 
drug.  A high ash content explains its unsuitable nature to be used as a drug  
Total Ash 
A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight. 
Water soluble ash 
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot water .The filter paper was dried
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash. 
Acid insoluble ash
The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1). The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed.
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BIO -CHEMICAL ANALYSIS OF KANDHA CHENDURAM  
 
The biochemical analysis of Kandha Chenduram  was carried out in the Biochemistry 
lab, NIS 
  
Appearance of sample Reddish  orange in colour 
S.No EXPERIMENT OBSERVATION INFERENCE
1. Solubility: 
a. A little (500mg) of the sample is 
shaken well with distilled water. 
b. A little (500mg) of the sample is 
shaken well with con. HCl/Con. 
H2So4 
 
 
Sparingly soluble 
 
 
Absence of Silicate 
2. Action of Heat: 
   A small amount (500mg) of the 
sample is taken in a dry test tube 
and heated gently at first and then 
strong. 
 
 
 
No White fumes 
evolved 
 
 
 
Absence of Carbanate 
3. Flame Test: 
  A small amount (500mg) of the 
sample is made into a paste with 
con. HCl in a watch glass and 
introduced into non-luminous part 
of the Bunsen flame. 
 
 
 
No Bluish green 
flame appeared 
 
 
 
Absence of copper 
4. Ash Test: A filter paper is soaked 
into a mixture of sample and dil. 
cobalt nitrate solution and 
introduced into the Bunsen flame 
and ignited
Yellow colour flame 
appeared 
Presence of Sodium
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Preparation of Extract: 
5gm of Kandha Chenduram is weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water. 
 
 I.Test For Acid Radicals 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
1 Test For Sulphate :
2ml of the above prepared extract is 
taken in a test tube to this added 2ml 
of 4%dil. ammonium oxalate solution. 
 
No cloudy 
appearance 
appeared 
 
Absence of sulphate 
2 Test For Chloride: 
2ml of the above prepared extracts is 
added with 2ml of dil-HCl is added 
until the effervescence ceases off. 
 
 
cloudy appearance 
appeared 
 
 
Presence of chloride 
3 Test For Phosphate: 
2ml of the extract is treated with 2ml 
of ammonium molybdate solution and 
2ml of con.HNO3
 
 
Yellow appearance 
not present 
 
 
Absence of 
Phosphate 
4 Test For Carbonate:
2ml of the extract is treated with 
2mldil. magnesium sulphate solution 
No Cloudy 
appearance present
Absence of 
Carbanate 
5 Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of 
dil. Acetic acid and 2ml dil.calcium 
chloride solution and heated.
No Cloudy 
appearance 
Absence of
fluoride and oxalate
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6 Test For Nitrate: 
1gm of the substance is heated 
with copper turning and 
concentrated H2SO4 and viewed 
the test tube vertically down 
 
 
No brown gas 
evolved 
 
 
Absence of nitarte 
7 Test For Sulphide: 1gm of the 
substance is treated with 2ml of 
con. HCL 
 
No Rotten Egg 
Smelling gas  
evolved 
 
Absence of 
sulphide 
8 Test For Nitrite: 
  3drops of the extract is placed on 
a filter paper, on that-2 drops of 
dil.acetic acid and 2 drops of dil. 
Benzidine solution is placed. 
 
 
No characteristic 
changes 
 
 
Absence of Nitrite
9 Test For Borate: 
  2 Pinches (50mg) of the 
substance is made into paste by 
using dil.sulphuric acid and 
alcohol (95%) and introduced into 
the blue flame. 
 
 
Bluish green colour 
flame not appeared 
 
 
Absence Of Borate
II. Test For Basic Radicals
1 Test For Lead:2ml of the extract 
is added with 2ml of dil.potassium 
iodine solution.
No Yellow 
Precipitate is 
obtained.
Absence of lead 
2 Test For Copper:One pinch 
(50mg) of substance is made into 
paste with con. HClin a watch 
glass and introduced into the non-
luminuous part of the flame.
No Blue colour 
precipitate formed. Absence of Copper
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3 Test For Aluminium: 
  To the 2ml of extract dil.sodium 
hydroxide is added in 5 drops to 
excess. 
 
No Yellow colour 
appeared 
 
 
Absence of 
Aluminium 
4 Test For Iron: 
a. To the 2ml of extract add 
2ml of thiocyanate ammonium 
solution 
b. To the 2ml of extract add 
2ml of  thiocyanate ammonium 
solution and 2ml  of con HNO3 . 
 
 
 Red colour 
appeared  
 
a.Absence of iron 
 
 
b.Presence of iron 
5 Test For Zinc: 
      To 2ml of the extract dil.sodium 
hydroxide solution is added in 5 
drops to excess and dil.ammonium 
chloride is added.  
 
 
White precipitate is 
not formed  
 
 
Absence of Zinc 
6 Test For Calcium:  
      2ml of the extract is added with 
2ml of 4% dil.ammonium oxalate 
solution
 
Cloudy appearance 
and white 
precipitate is 
obtained 
 
Presence of 
Calcium
7 Test For Magnesium: 
To 2ml of extract dil.sodium 
hydroxide solution is added in drops 
to excess. No White 
precipitate is 
obtained 
Absence Of 
Magnesium
8 Test For Ammonium:
To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. No Brown colour 
appeared 
Absence of 
Ammonium 
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9 Test For Potassium:  
   A pinch (25mg) of substance is 
treated off with 2ml of dil.sodium 
nitrite solution and then treated with 
2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
 
No yellowish 
precipitate is 
obtained 
 
Absence of  
Pottasium 
10 Test For Sodium: 
   2 pinches (50mg) of the substance is 
made into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
 
Yellow colour flame 
appeared
Presence of sodium
11 Test For Mercury:  
   2ml of the extract is treated with 2ml 
of dil.sodium hydroxide solution.  
 
Yellow precipitate is  
not obtained 
 
Absence of Mercury 
12 Test For Arsenic:  
   2ml of the extract is treated with 2ml 
of dil.sodium hydroxide solution. 
 
No Brownish red 
obtained 
 
Absence of Arsenic 
III.Miscellaneous
1 Test For Starch:
2ml of extract is treated with weak 
dil.iodine solution
No blue colour 
devolopped 
Absence of Starch
2 Test For Reducing Sugar:
5ml of Benedict's qualitative solution is 
taken in a test tube and allowed to boil 
for 2 minutes and added 8 to 10 drops 
of the extract and again boil it for 2 
minutes. The colour changes are noted 
Brick red colour not 
devolopped
Absence of reducing 
sugar 
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3 Test For The Alkaloids: 
a) 2ml of the extract is treated with 2ml 
of dil.potassium lodide solution. 
b)  2ml of the extract is treated with 2ml 
of dil.picric acid. 
c)  2ml of the extract is treated with 2ml 
of dil.phosphotungstic acid.
 
 
 
Yellow colour not 
developed 
 
 
 
Absence of alkaloid 
4 Test For Tannic Acid:  
  2ml of extract is treated with 2ml of 
dil.ferric chloride solution 
 
 
No black precipitate 
obtained 
 
 
Absence of Tannic 
acid 
5 Test For Unsaturated Compound:
  To the 2ml of extract 2ml of diluted 
Potassium permanganate solution is 
added.  
Potassium 
permanganate 
solution is not 
decolourised 
Absence of 
Unsaturated 
compounds 
6 Test For Amino Acid: 
2 drops of the extract is placed on a 
filter paper and dried well. 20ml of 
Biurette reagent is added.
 
Violet  colour   
developed 
 
Presence of
Aminoacid 
7 Test For Type Of Compound: 
2ml of the extract is treated with 2 ml 
of dil.ferric chloride solution.
No Green, red, 
violet. Blue colour 
developed
Absence of Oxy
quinole, Pinephrine
and Pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and meconic 
acid are absent
Apomorphine 
salicylate and 
Resorcinol are absent
Morphine, Phenol 
cresol and hydro 
uinone are absent 
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ICP OES 
 
METHODOLOGY: 
ICP, abbreviation for Inductively Coupled Plasma, is one method of optical 
emission spectrometry. When plasma energy is given to an analysis sample from outside, 
the component elements (atoms) are excited. When the excited atoms return to low 
energy position, emission rays (spectrum rays) are released and the emission rays that 
correspond to the photon wavelength are measured. The element type is determined based 
on the position of the photon rays, and the content of each element is determined based on 
the rays' intensity.  
To generate plasma, first, argon gas is supplied to torch coil, and high frequency 
electric current is applied to the work coil at the tip of the torch tube. Using the 
electromagnetic field created in the torch tube by the high frequency current, argon gas is 
ionized and plasma is generated. This plasma has high electron density and temperature 
(10000K) and this energy is used in the excitation-emission of the sample. Solution 
samples are introduced into the plasma in an atomized state through the narrow tube in 
the center of the torch tube. 
 
Sample preparation: 
Solids cannot be analyzed directly. Such samples should be made into clear 
aqueous medium quantitatively. When acids are used to prepare solutions care 
should be taken. The concentration of the acids in the final provided solution 
should not be more than 2% v/v. highly acidic and organic solutions cannot be 
analyzed. As a guide line weigh exactly, around 200mg of substance and dissolve 
in 5mL of 5% of water or aqua regia or whatever acid to make 100mL of final 
solution. Make proper dilutions, if necessary. Free HF should not present in the 
final solution to be aspirated. 
Ideal concentration is around 100 ppm of the element of interest.
Total dissolved solids should be not more than 0.2% w/v in the final solution.
Very dilute solution may not give reliable results. Each element has a detection 
limit.
A minimum solution volume of 25 ml is necessary for analysis.
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 ed or aspirated into an 
given wavelength will be proportional to a particular elemental ion concentration. 
The intensity is calibrated with known standard concentration. For accurate 
quantitative results It is necessary to simulate the sample matrix condition with 
that of the standard. Each element generally will have many emission lines and the 
sensitivity is different for each of this wave length. When more than one element 
is present it is quite common that some emission lines interfere due to 
overlapping.  
It is preferable to use plastic containers for sample handling and preserving 
samples for ICP-OES analysis. Glass containers can give problems especially 
when analyzing certain metal ions at low concentration.  
 Thus the Sample of Kandha Chenduram  was prepared.  
Then, the prepared sample was analysed in the ICP-OES technique
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TOXICOLOGICAL STUDY 
 
ACUTE AND SUB ACUTE TOXICITY STUDY ON KANDHA CHENDURAM 
Animals  
 Mice of either sex weighing 25-30gm and rats weighing 210-240gm were 
obtained from the animal house of Vels University. The animals were used with the 
approval of the Institute Animal Ethics Committee and obtained from Vels University, 
Chennai. They were fed with a balanced standard pellet diet and maintained under 
standard laboratory conditions, providing 24-280C temperature, standard light cycle (12 
hr light, 12 hr dark) and water ad libitum. Animals were kept in cages with raised floors 
of wide mesh to prevent coprophagy. Animal welfare guidelines were observed during 
the maintenance period and experimentation. The rats were randomly assigned to control 
and different treatment groups, six animals per group. The animals were acclimatized for 
one week under laboratory conditions.  
 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Kandha Chenduram was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight. After the substance has been administered, food 
was withheld for a further 2 hours in mice. The animals were observed continuously for 
the first 4 hr and then each hour for the next 24 hr and at 6 hourly intervals for the 
following 48 hr after administering of the test drug, to observe any death or changes in 
general behaviour and other physiological activities. Single animals are dosed in sequence 
usually at 48 hr intervals. However, the time interval between dosing is determined by the 
onset, duration, and severity of toxic signs. Treatment of an animal at the next dose was 
delayed until one is confident of survival of the previously dosed animal. 
Observation of toxicity signs:  
General behavior, respiratory pattern, cardiovascular signs, motor activities, 
reflexes, change in skin and fur, mortality and the body weight changes were monitored 
daily. The time of onset, intensity, and duration of these signs, if any, was recorded.  
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ACUTE ORAL TOXICITY STUDIES 
 Acute oral toxicity study was performed as per OECD-425 guidelines. Mice (n = 
6) of either sex selected by random sampling technique were used for acute toxicity 
study. The animals were kept fasting for overnight providing only water, after which the 
Kandha Chenduram in 2% CMC was administered orally at the different dose levels in up 
and down dosing schedule according to body weight by gastric intubation and observed 
for 14 days.  
 
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while Groups II, III and IV were administered daily with the Kandha 
Chenduram (p.o.) for 28 days at a dose of 12.5, 25 and 50mg/kg respectively. The 
animals were then observed daily for gross behavioural changes and any other signs of 
subacute toxicity. The weight of each rat was recorded on day 0 and weekly throughout 
the course of the study, food and water consumption per rat was calculated. At the end of 
the 28 days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.
Hematological and blood biochemical analyses: 
At the end of the study, all animals were kept fasted for 16-18 hr and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
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Necropsy:  
All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically.
 
Statistical analysis 
Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
RESULTS AND DISCUSSION
 Animals were shown significant toxic clinical signs during the dosing period of 28 
days. All animals from control and all the treated dose groups not survived throughout the 
dosing period of 28 days and it was found two animal dead after 24 days of treatment in 
moderate and high dose. Results of body weight determination of animals of control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. During dosing period, the quantity of food consumed by animals from 
different dose groups was found to be comparable and normal with that of control 
animals.
Ophthalmoscopic examination of animals in control and Kandha Chenduram 
treated group revealed minor but remarkable abnormality. Urine analysis data of control 
group and treated group of animals determined in week 4 did not reveal any significant 
abnormalities except colour and pH changes. Comparison of organ weights of treated 
animals with respective control animals on day 28 was found to be comparable. Gross 
pathological examination of animals in control as well as the treated groups did not reveal 
any abnormalities.
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The results of haematological investigations conducted on day 28, revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls; However, the increase or decrease in the 
values obtained was within normal biological and laboratory limits. Results of 
Biochemical investigations revealed the few significant changes in the values of different 
parameters studied when compared with those of respective controls; however, the values 
obtained were within normal biological and laboratory limits.  
 
CONCLUSION 
 Based on these findings, toxic effect was observed at both 25 and 50mg/kg of 
Kandha Chenduram treated via oral route over a period of 28 days. So, it can be 
concluded that the Kandha Chenduram can be prescribed for therapeutic use in human 
with the strict dosage reductions of upto 12.5mg/kg. body weight p.o.
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PHARMACOLOGICAL STUDYXXVII 
 
EVALUATION OF HYPOGLECEMIC ACTIVITY OF KANDHA CHENDURAM 
IN ALLOXON INDUCED DIABETIC RATS 
 
MATERIALS AND METHODS: 
Animals 
 Wistar albino rats (8 10 weeks) of both sexes were obtained from the animal 
house of School of Pharmacy, Vels University, Chennai. Before and during the 
experiment, rats were fed with standard diet (Sai durga foods, Bangalore). After 
randomization into various groups and before initiation of experiment, the rats were 
acclimatized for a period of 7 days under standard environmental conditions of 
temperature, relative humidity, and dark/light cycle. Animals described as fasting were 
deprived of food and water for 16 hrs ad libitm (No: 
XIII/VELS/43/2000/CPCSEA/IAEC/08.08.2012)
Drug administration
The drugs to be administered were calculated and suspended in vehicle (2% w/v 
suspension of carboxy methyl cellulose (CMC) in water 10 ml/kg b.w). The drug was 
administered continuously for 14 days orally using an oral feeding tube. The results were 
compared with that of the standard drug Glibenclamide which was also given 
continuously for 14 days. 
Oral Glucose Tolerance Test 
Rats were divided into five groups containing six animals in each group. All 
animals fasted before treatment. Group I was kept as vehicle control which received 2% 
w/v suspension of Carboxy Methyl Cellulose p.o., Group II received glucose only (2g/kg, 
p.o.), Group III received Kandha Chenduram 25 mg/kg, Group IV received Kandha 
Chenduram 50mg/kg. The rats of Group V were treated with Glibenclamide. Blood 
samples were collected by puncturing the retro orbital sinus just prior to drug 
administration, and 30, 90 minutes after loading glucose. Serum glucose level was 
measured immediately. 
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Experimental Design 
Five groups of rats, six in each received the following treatment schedule.
Group I: Normal control (saline). 
Group II: Alloxan treated control (150mg/kg.ip). 
Group III: Alloxan (150mg/kg.i.p) + Kandha Chenduram 25mg/kg, p.o, 
Group IV: Alloxan (150mg/kg.ip) + Kandha Chenduram 50mg/kg, p.o
Group V: Alloxan (150mg/kg.ip)+Standard drug, Glibenclamide(5mg/kg, p.o). 
 Kandha Chenduram and standard drug glibenclamide (5mg/kg) and saline were 
administered with the help of feeding cannula. Group I serve as normal control, which 
received saline for 14 days. Group II to Group V are diabetic control rats. Group III to 
Group V (which previously received alloxan) are given a fixed dose Kandha Chenduram 
(25mg/kg, p.o), (50mg/kg, p.o) and standard drug glibenclamide (5mg/kg) for 14 
consecutive days.
 
Induction of Diabetes in Experimental Animals
 Rats were made diabetic by a single intraperitoneal injection of alloxan 
monohydrate (150mg/kg). Alloxan was first weighed individually for each animal 
according to the body weight and then solubilized with 0.2ml saline just prior to injection. 
Two days after alloxan injection, rats with plasma glucose levels of >150mg/dl were 
included in the study. Treatment with Kandha Chenduram was started 48 hr after alloxan 
injection. 
Collection of Blood Sample and Blood Glucose Determination 
Blood samples were drawn from tail tip of rat at weekly intervals till the end of 
study. Fasting blood glucose estimation and body weight measurement were done on day 
1, 7, and 14 of the study. Blood glucose estimation was done by one touch electronic 
glucometer using glucose test strips. On day 14, blood was collected from retro-orbital 
plexus under mild ether anesthesia from overnight fasted rats and fasting blood sugar was 
estimated.
Serum was separated and analyzed for serum cholesterol, serum triglycerides, 
serum HDL, serum LDL was estimated. The whole pancreas from each animal was 
removed after sacrificing the animal and was collected in 10% formalin solution, and 
immediately processed by the paraffin technique. Sections of 5 thickness were cut and 
stained by haematoxylin and eosin for histological examination. 
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Statistical Analysis 
 All the values of body weight, fasting blood sugar, and biochemical estimations 
were expressed as mean±standard error of mean (S.E.M.) and analyzed for ANOVA and 
Dunnet's t-test. Differences between groups were considered significant at P <0.01. 
RESULTS AND DISCUSSION
 Diabetes mellitus is considered as one of the five leading causes of death in the 
world. In modern medicine no satisfactory effective therapy is still available to cure 
diabetes mellitus. There is increasing demand by patients to use natural products with 
hypoglycemic activity due to side effects associated with the use of insulin and oral 
variety of animal species by damaging the insulin-secreting cells of the pancreas. Though 
not routinely used anymore, the oral glucose tolerance test (OGTT) is the gold standard 
for making the diagnosis of type 2 diabetes. It is still commonly used for diagnosing 
gestational diabetes also. 
Literature sources indicate that alloxan rats are hyperglycemic. The use of alloxan 
-cells even though the 
-cells and 
regeneration is possible. The acute oral toxicity study of Kandha Chenduram showed no 
mortality upto 250mg/kg. Since the Kandha chenduram was identified with remarkable 
toxicity at the higher dose in the acute toxicity study. Hence the stability and tolerance 
was observed at 250mg/kg dose level. From this one tenth dose was considered as median 
or therapeutic dose for the further pharmacological evaluation.
Administration of alloxan (150mg/kg, i.p.) lead to 1.2-fold elevation of fasting 
blood glucose levels, which was maintained over a period of 2 weeks. Alloxan caused 
body weight reduction (P<0.01), which is reversed by Kandha Chenduram at the dose 
(25mg/kg) is more effectively after 14 days of treatment. The supplementation of Kandha 
Chenduram improved the glucose tolerance in the fasted normal rats. After that serum 
glucose level was lowered significantly (P<0.05) at 30 minutes and varied significantly 
(P<0.01) lowered at 90 minutes. On repeated administration of Kandha Chenduram at 
doses of 25mg and 50mg/kg b.w. for 14 days, a significant (P < 0.01) dose-dependent 
decrease in blood glucose of the diabetic rats was seen as compared to the vehicle-treated 
control group.
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The control rats had the blood glucose level 74.64±2.4mg/dl while untreated 
diabetic rats showed 225.17±16.64mg/dl blood glucose level. Kandha Chenduram treated 
rats showed significant reduction in blood glucose levels. On day 5 of treatment at 25mg 
dose of Kandha Chenduram reduced the blood glucose level to 186.20±10.15mg/dl 
(P<0.01) while 50 mg dose reduced the level to 162.45±12.00mg/dl (P<0.01). 
Glibenclamide treated rats showed expected hypoglycemic effects i.e. blood glucose level 
of 120.10±3.12mg/dl. On day 14, the glucose level was reduced more significantly 
109.17±2.48 and 102.56±2.33 in both the dose of Kandha Chenduram and the results are 
comparable to the effects shown by standard Glibenclamide.  
  
Diabetes mellitus is a chronic disorder caused by partial or complete insulin 
deficiency, which produces inadequate glucose control and leads to acute and chronic 
complications. Premature and extensive arteriosclerosis involving renal, peripheral, and 
cardiovascular vessels remain the major complication of diabetes mellitus. Alteration in 
the serum lipid profile is known to occur in diabetes and this is likely to increase the risk 
for coronary heart disease. A reduction in serum lipids, particularly of the LDL and 
VLDL fraction and triglycerides, should be considered as being beneficial for the long-
term prognosis of these patients. In the biochemical evaluation the Kandha Chenduram 
altered the deviated parameters towards normal. Particularly, the total cholesterol was 
71.28 ± 1.5, 76.12±1.6 (P<0.01) and the triglyceride was 68.2±2.17, 74.6 ± 2.35 (P<0.01) 
and the HDL was 132.30±0.41, 135.1±0.30 (P<0.01) and the LDL was 61.46±2.25, 
53.22±0.62 (P<0.01) at the dose levels 25 and 50mg/kg of Kandha Chenduram 
respectively which was comparable with that of standard drug treated group values.
Lowering of blood glucose and plasma lipid levels through dietary modification 
and drug therapy seems to be associated with a decrease in the risk of vascular disease. 
Diabetic rats were observed to have increased plasma lipids, which are responsible for 
several cardiovascular disorders. The higher lipid levels seen in diabetic rats were due to 
increased mobilization of free fatty acids from peripheral depots and also due to lipolysis 
-cells of the 
pancreas and potentiation of insulin secre -cells; the increase in 
insulin secretion and the consequent decrease in blood glucose level may lead to 
inhibition of lipid peroxidation and control of lipolytic hormones.
76 
In present investigation, it was observed that Kandha Chenduram can reverse the 
effects of Alloxan induced diabetes to a significant level. Possible mechanisms brings 
about its hypoglycemic action may be by increasing either the pancreatic secretion of 
-cells of islets of langerhans. This study results indicates that Kandha 
Chenduram have significant anti-hyperglycemic activities in alloxan-induced 
hyperglycemic rats without major change in body weight and improved the body weight 
& lipid profile along with serum creatinine, serum urea and serum alkaline phosphatase. 
The renewal of  cells in diabetes have been studied in several animal models. The total  
cell mass reflects the balance between the renewal and loss of these cells. It was also 
suggested that regeneration of islet ß cells following destruction by alloxan may be the 
primary cause of the recovery of alloxan-injected rats from the effects. Kandha 
Chenduram has been shown to act by  cell regeneration. Hence the above discussion 
reveals that Kandha Chenduram at high dose (50mg/kg) is more effective as standard that 
is, glibenclamide (5mg/kg). Histopathological studies confirm the healing of pancreas, by 
Kandha Chenduram, as a possible mechanism of their antihyperglycemic activity.
  
Histopathological studies showed normal acini and normal cellular population in 
the islets of Langerhans in pancreas of control rats. Severe damage to the islets of 
Langerhans and reduced dimensions of islets results damage of pancreas in alloxan-
treated diabetic control rats. The partial restoration of normal cellular population and 
enlarged size of -cells with hyperplasia were shown by Kandha Chenduram. Restoration 
of normal cellular population size of islets with hyperplasia by Glibenclamide was seen.
CONCLUSION 
-
cells of the islets of Langerhans. Kandha Chenduram did not show any effect on normal 
blood sugar levels but it effectively reversed the alloxan-induced changes in the blood 
-cell population in the pancreas. This could be due to potentiation of 
the insulin effect of plasma by increasing the pancreatic secretion of insulin from existing 
-cells of islets of Langerhans or its release from bound insulin. Diabetes mellitus is 
possibly the world's largest growing metabolic disease, and as the knowledge on the 
heterogeneity of this disorder is advanced, the need for more appropriate therapy 
increases. Traditional medicines like Kandha Chenduram can be used for a range of 
diabetic complications with lesser side effects.
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DISEASE ASPECT  
SIDDHA ASPECT 
 
ÁÐ§Á¸õ 
 According to siddhars the imbalance of Tridosha causes totally 4448 diseases to 
human being.Among them megarogam is considered to be the emperor of diseases.
 
"¬ÁôÀ¡ ÁÉ¢¾÷ ¦ºö¾ ¸ýÁò¾¡§Ä 
   «Ã¸Ã¡ §Á¸¦ÁýÈ Ã¡º¡Å¡§Ä.XXVII I  
Madhumegam has been described by many siddhars in their texts. The aetiology, 
pathogenesis, classification,clinical features, diagnosis and prognosis have been dealt in 
detail in these texts. 
§ÅÚ ¦ÀÂ÷:  ¿£Ã¢Æ¢×  
  ¦ÅÌãò¾¢Ãõ  
  ÁÐ À¢Ã§Á¸õ  
  É¢ôÒ ¿£÷  
  §Á¸ ¿£÷  
  ¾¢ò¾¢ôÒ ¿£÷  
 
Âø:
 It is a clinical condition characterized by  frequent passage of   urine  more  than 
the normal resulting in deterioration and diminution of seven thathus. 
" É¢ôÀ¡É É¢ôÀøÄ ® Åó¾¡Îõ 
´Õ Ðª¢Å¡ö Å¢ð¼¡÷¨¸ô À¢½¢Â¡ö §¾¡ýÚõ"XXIX
The above description quotes that ant and flies are attracted to the site of voided 
urine and when the urine is heated it gives honey odour .
"«ñ¨ÁÂ¡ÂÊì ¸ÊìÌ ¿£Ã¢ÈíÌ
¸ÊìÌ «¨Ã¿¡Æ¢ ¾É¢§Ä ¸¡Ïõ
¦Åñ¨ÁÂ¡É ¾ÊÂ¾É¢üÈ¡ý À¢ÊìÌõ 
Á¢ì¸¡É º¼õ ¦ÅÖòÐ §ÁÉ¢ ¸ýÚõ"XXX
This poem comprises the clinical features of Madhumegam
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§¿¡ö ÅÕõÅÆ¢: 
 "§¸¡¾Â÷ ¸ÄÅ¢ §À¡¨¾ ¦¸¡Øò¾ Á£ý ¨Èîº¢ §À¡¨¾ 
   À¡ÐÅ¡ö ¦¿öÔõÀ¡Öõ ÀÃ¢×¼ý ¯ñÀ£Ã¡¸¢ø 
   §º¡¾ À¡ñÎÕÅ Á¢ì¸ Íì¸¢Ä À¢Ã§Á¸ó¾¡ý 
   µÐ ¿£Ã¢Æ¢×§ºÃ ×ñ¦¼É«È¢óÐ ¦¸¡û§ª"XXXI 
                            
The above poem quotes that excessive intake of rich food like ghee, fish, milk, 
toddy and excessive indulgence in sex leads to madhu megam.
"¯üÀÅ¢ìÌõ À¡ø ¦¿öÂ¡ø ¨Èîº¢ ¦¸¡ûªø 
×Ã¢¨ºÂ¡Â Á£ó¾ýÉ¡ø «ÕÅ¢Õò¾ 
   Áó¾í¸û ¾¨ÉÒº¢ò¾ø §Å¸¡ô Àñ¼í 
    
   ÌÈ¢ò¾ ¿¢ò¾¢¨Ã ¾Å¢÷ò¾ø «ì¸¢É¢ Áó¾õ 
   ¾üÀÅ¢ìÌó ºÃ£Ãó¾¡ý Á¢¸ô ÀÕò¾ü  
   ºïºÄó¾¡ý Á¢¸ôÀÂò¾¡ø ¾Ã¢ìÌõ §¿¡§Â"XXXI I 
                          
" ÂõÀ§Å ¬Ú Ìªõ À¢ýÉï ¦ºö¾ø 
²üÈÁ¡ö Á¡üÈ¡ý ¦Àñ ºí¸õ ¦ºö¾ø 
ÀÂõÀ§Å À¡Ä÷¸Ùì ¦¸¡ª¢òÐ ¾¢ýÉø 
¿¨Ã âò¾ ¦¸¡í¨¸Â¡û ¿¡Â¸ý §Á¡¸ò¾¡ø 
Á¨È §À¡üÚí ¸ÕôÀò¾¢ø Åª÷ó¾Ð §Á¸§Á"XXXI I I
º¢ÃÍ ÁðÎõ ¦ÅóÐÕ¸¢ì¸É§Ä Á£È¢ì 
Ìü¢Ô¼§É §Á¸ó¾¡ý ¦¸¡Î¨Á ¦ºöÐ
Ì¨ÈóÐ ÅÕõ ¾¡Ð¦ÅøÄ¡õ ÌýÈ¢ô§À¡Ìõ"XXXIV
"¸ýÉ¢ ÁÂì¸ò¾¡ø ¸ýÊÎ §Á¸§Á"XXXV
79 
"¿¢¨È âò¾ ¦¸¡í¨¸Â¡û ¿¡Â¸ý §Á¡¸ò¾¡ø 
   Á¨È §À¡üÚõ ¸ÕôÀò¾¢ø Åª÷ó¾Ð §Á¸§Á"XXXVI 
 
"¸¢Ãó¾¢ Òñ½¢Ã½ §Á¸ì¸£º¸¦ÉÛó ÐýÁ¡÷ì¸ý 
   «Õó¾¾¢ ±ýÛõ À¡ïº¡Ä¢ Âý¨É¨Âì ¸ñÏüÈ¡§É"XXXVII 
                           
The conclusion from the above said, all Siddhars attribute Diabetes mainly due to 
excessive indulgence in sex which results in depletion of total strength of body as a 
whole, making the individual susceptible to this disease. 
 
Psychosomatic Factors:
 
Yugimunivar and other Siddhars stress a great importance to Psychosomatic 
factor. All antisocial activities ultimately result in subjective guiltiness and 
psychosomatic stress resulting in disease like diabetes, peptic ulcer and hypertension. 
 
"Á¾í¦¸¡ñÎ ¦ÀÃ¢§Â¡¨Ã ¨Å¨¸Â¡Öõ 
    Á¡¾÷ ¸üÒ¿¢¨Ä¨Á ¾ý¨É «Æ¢ì¨¸Â¡Öõ 
    À¾ý¦¸¡ñ¼ º¢Å§Â¡¸¢ º¡Àò¾¡Öõ 
ÀòÐÅ¨¸ º¢§ÄüÀÉí¸û §Á¸¿£Ã¡õ"XXXVI I 
¸ýÁ§¿¡ö:
In the views of Theraiyar, Agasthiar and Thirumoolar, Madhu megam also occurs 
as a result of bad deeds commited in his or her past or previous births. 
"¬ÁôÀ¡ ÁÉ¢¾÷ ¦ºö¾ ¸ýÁò¾¡§Ä 
«Ã¸Ã¡ §Á¸¦ÁýÈ Ã¡º¡Å¡§Ä 
¸¡ÁôÀ¡ Ä¾¢É¡ø Àº¢ÔôÀ ¿¡Öí 
¨¸ì¸¼í¸¡ §¿¡ö¸ø ÅÕõ ¸÷Áò¾¡§Ä"XXXIX
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§¿¡ö ±ñ: 
¦º¡øÖ¦ÁýÚ §¸ð¼×¼ý º¢ÅÛ Áô§À¡ 
    §¾Å¢¨Âò¾¡ýÓ¸õ À¡÷òÐ Å¡Ã¡ö §¾Å¢ 
    «øÖ¦Áý§È §Á¸ÁÐ ÃñÎ ÀòÐ  
    Á¸¢úóÐ ¿£ §¸Ù¦ÁýÚ ÅºÉ¢ò¾¡§Ã"  
 
"ÅºÉ¢ò¾ §Á¸ÁÐ ÃñÎ ÀòÐ  
    Å¡¾ò¾¢ü À¢Èó¾ ºÄõ ¿¡§ÄÂ¡Ìõ 
    À¢ºý¢ò¾ À¢ò¾ò¾¢ ÖüÀÅ¢ò¾ 
    §ÀÃÉ ºÄó¾¡Û Á¡ÚÁ¡Ìõ 
    §¾ºÉ¢ò¾ §ºðÎ Áò¾¢ø ¯÷ÀÅ¢ò¾  
    º£ÃÉ ºÄó¾¡Ûõ Àò§¾Â¡Ìõ 
    ºÉ¢ó¾ ¾Û¨¼Â Ì½¡Ì½í¸û"XL 
                           
The saint Yugi classified Megam into 20 types. That is Vatham-4, Pitham-6, 
Kabam-10 types. 
 
"¾ì¸¾¡Ã½¢ Á¡É¢¼ò§¾¡÷¸û §¸ûÀì¸ Á¡ºÄõ Å¨¸ÔÁ¡§Á 
¿ì¸¿¡Â¸ý ¿¡Â¸¢ì§¸ ¦º¡øÁ¢ì¸ ¿ó¾¢ Å¢ªõÀ¢ Å¢¾¢ò¾§¾" 
¸Æ¢Ôõ §ºòÐÁõÀò¾¡Öõ ¦º¡øÖõ ¿¡Äïº¡ö§¾¡ýÚõ 
ÅÆ¢ÔõÅ¡¾õ ¿¡ý¸¡§Á Á¡Õ¾Å¢ú¾ó ¾ýÉ¡§Ä"XLI
As per Thirumoolar Vaidyam 600, Prameham is also called as Premeham 
Neerizhivu. In Agasthiyar texts and "Yugi muni Vaidhya Chinthamani 800" 
Madhumegam is one among the 20 varieties of Prameham. Each author who have dealt 
mega disorders have differently classified them under three doshas and have given names 
according to their concept. But the number, signs and symptoms of the classified 
disorders are almost identical in the description of the disease. Different types of clinical 
disorders have been described on the basis of colour, consistency, taste and smell etc. 
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Å¨¸¸û XLII  
Å¡¾ò¾¢ý ¸£ú:  
 ¦¿öÁ½ ¿£÷  
 ÀÍÁ½ ¿£÷   
 °ñÁ½ ¿£÷ 
 º£úÁ½ ¿£÷ 
  
À¢ò¾ò¾¢ý ¸£ú:  
 Â¡¨Éì ¦¸¡ØôÒ¿£÷  
¸üÈ¡¨Æ ¿£÷
 Íñ½¿£÷  
 É¢ôÒ ¿£÷ 
 Àª¢íÌ ¿£÷  
 ÓÂüÌÕ¾¢ ¿£÷ 
¸Àò¾¢ý ¸£ú:  
 Åº¡ ¿£÷  
 ¦¾ª¢ ¿£÷  
 ã¨ª ¯ÕìÌ¿£÷  
ª ¿£÷
¸û ¿£÷ 
Íì¸¢Ä ¿£÷ 
§¾ý ¿£÷ 
¯ôÒ ¿£÷ 
¸Ø ¿£÷ 
¨Èîº¢ ¿£÷
Above 21 varieties are as followsXLIII,
1.Muyarchiyal vantha Megam (Self acquired-6 ) 
2.Karuppathal vantha Megam (Hereditary (or) Constitutional-5 ) 
3.Palakkaarana Megam (Miscellaneous-7 )
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ÌÈ¢Ì½í¸û: 
ÜÈ¡É §Á¸ÁÐ ÕÀÐìÌõ  
    Ì½ó¾¨É º¢Åý¦º¡øÄ §¾Å¢§¸ð¸  
¾¡È¡É ¾¡¸¦Á¡Î §º¡¸§Á¸óò  
    ¾Ã¢Â¡Áø ¿£Ã¢Æ¢¾ Ä¢ÕÁø ãîÍ 
¬È¡É «Õº¢ºò¾¢ º¢ò¾ À¢Ã¨Á
«Êì¸ÊìÌò ¾ñ½£÷¾¡ ÉýÉí §¸ð¼ø
®È¡É ÎôÒìÌû ¸ÎôÒ ¸¡½ø  
±ÖõÒ ÆüÈ§Ä¡ ¦¼Ã¢×ñ¼¡§Á"
±Ã¢§Å¡Î ºÃ£Ã¦ÁøÄ¡ Á¨ÈÀð¼¡ü §À¡ø
±Æ¢Ö¼õÒ §¿¡¾ø ¿¢ò¾¢¨Ã Â¢øÄ¡¨Á
ÅÃ¢§Å¡Î Á¡ö×¦Áò¾ ×õÀÈ¢ò¾ø
ÁÉÐ ºïºÄôÀÎ¾ø ¸¡üÚ §Åñ¼ø
¦ÁÃ¢§Å¡Î §ÁøãîÍ Á¢¸×ñ¼¡¾ø
Å¢ì¸§Ä¡Î ÁÂì¸ó¾¡ý ¦Áò¾ì ¸¡½ø
¦¾Ã¢¦Å¡Î §¾¸¦ÁíÌõ ¦Åª¢Õñ¼¡¾ø
§¾¸¦Áò¾ Å¡§Ä¡ÀôÀÎ¾ø ¸¡§½
¾ý¨ÁÂ¡ö ºÄó¾¡Ûõ ÀÍôÒ Áïºû  
¾¡É¢ÈíÌõ À£ºÓí §¸¡ºÓí ¸ÎìÌõ
«ñ¨ÁÂ¡ ÂÊì¸ÊìÌ ¿£Ã¢ÈíÌ
ÁÊì¸ÊìÌ «¨Ã¿¡Æ¢ ¾É¢§Ä¾¡Ûõ 
¦Åñ¨ÁÂ¡Â ÊÂ¾É¢ü È¡ýÀ¢ÊìÌõ
Á¢ì¸¡ýº¼õ ¦ÅÙòÐ §ÁÉ¢¸ýÚõ
Àñ¨ÁÂ¡öô ÀïºÅ¡ñ¼ ¾É¢ü¦¸¡øÖõ
À¸÷¸¢ýÈÁÐ §Á¸ò¾¢ý À¡íÌ¾¡§É"XLIV
¦À¡Õû:
¿£÷§Åð¨¸ 
«Êì¸Ê ¿£Ã¢Æ¢¾ú
ÕÁø
§ÁøãîÍ
Í¨ÅÂ¢ý¨Á
º¢ò¾õ ¸Äí¸ø
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 «Êì¸Ê ¿£Õõ §º¡Úõ §¸ð¼ø  
 ÎôÒìÌ «Îò¾ ±ÖõÒ ¯ ÆýÚ ±Ã¢¾ø  
 ¯¼ø ¦ÁÄ¢óÐ §¿¡¾ø  
 àì¸Á¢ý¨Á  
 Å¡Ô Á¢ÌóÐõ ÀÃ¢¾ø  
 ÁÉì¸Äì¸õ  
 ¸¡üÚ §ÅñÎ¾ø  
 Ý¼¡¸ ãîÍ ¦Åª¢Â¡¾ø  
Å¢ì¸ø
 ÁÂì¸õ Á¢¸ì ¸¡½ø  
¯¼ø Á¢¸×õ ¦ÅÙòÐô §À¡¾ø
 
«Åò¨¾¸û :
Complications of madhumegam as "Avathaigal". There are ten avathaigal 
described one by one as follows. 
   
"¸¡½§Å Ó¾ÄÅò¨¾ ºÃ£Ãó¾¡Ûí 
    ¸ÉÁ¡¸ô ÀÕò¾¢Õ¸¢ ¿£÷òÐÅ¡Ãõ  
§Å½§Å Åñ¼¡ì¸¢ Â¸Äõ ÀñÏ  
    Á¢ì¸ Å¢Ãñ¼¡«Åò¨¾ Å¢ªõÀì §¸ª¡ö  
ã½§Å ãò¾¢Ãô À£¨¼ÔÁ¡î Íì¸¢Ä  
     
¿¡½§Å ãýÈ¡Ì ÁÅò¨¾ì Ìò¾¡ý 
¿¡ÅÈÙõ Å¡ÔÅÐ Á£Úó¾¡§É 
¾¡È¡É ¿¡Ä¡ÁÅò¨¾ Âí¸ ¾¡¸ï
ºýÉ¢ÂÐ À¡¾Óñ¼¡ ¨Áó¾ Åò¨¾ò
§¾ÈÉ¡ ¿£÷¦ÀÕÌó ¾¡Ð ¿ð¼õ
¿¢¨ÄÂ¡Ù ÁÅò¨¾ Ô¼ü¸¢¨¼ ¦¸¡ûª¡Ð
ã½¡É ã÷î¨º ÅÕ§Á ÆÅò¨¾ 
Á¢ì¸Åïº §Ã¡¸ïÍÅ¡º §¾¸ º¡ðÊÂõ
²É¡É ±ð¼¡Å ¾Åò¨¾ò ¾¡§É
±Ø¸¢Ãó¾¢ À¢ª¨ÅÔó ¾¡ýÁ¢¸ ×ñ¼¡§Á
¯ñ¼¡Ì ¦Á¡ýÀ¾¡ ÁÅò¨¾ §¸ª¡ö
´Øì¸¡É Å¡º¡Ãí ¸¢ÕÁ¢ Ôñ¼¡õ
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ÀñÀ¡É Àò¾¡ó ¾¡ÉÅò¨¾ì §¸ª¡ö  
À¡ÃÁ¡ö ºÂí¦¸¡ñÎ ÀÃòÐì §¸Ìõ"  
¦Åñ¼¡Ì §Á¸ó¾¡ É¢ÕÀÐìÌõ Å¢ªí¸¢Â  
    §¾¡÷¾º ÅÅò¨¾ Å¢ÅÃï ¦º¡ý§É¡õ  
«ñ¼¡Ìï º¡ò¾¢ÂÅ º¡ò¾¢Â Á¢ÃñÎ  
ÁÈ¢óÐ¦¸¡ñÎ Å¼Å¡¸ ÅÅ¢ú¾ï ¦ºö§Â!XLV
¦À¡Õû:
¿£Ã¢Æ¢Å¢ø ¸¡Ïõ ÀòÐ «¨Åò¨¾¸û ´ýÈýÀ¢ý ´ýÈ¡¸ ¦¾¡¼Õõ. 
«¨Å¸û:
1. §¿¡ö §¾¡ýÚÅ¾üÌ Ó¾üÌÈ¢Â¡¸ ¯¼ø ¦ÀÕòÐì ¦¸¡ñ§¼ ÅÕÅ§¾¡Î 
¿£÷ôÒ¨Æ «¸ýÚ ÅÕõ.
2. ¿£÷ ¦ÀÕ¸¢ Æ¢Å§¾¡Î ¦Åñ½£÷ ¦¸ðÎ ¯¼Ä¢ý ´ª¢ ÌýÈ¢ì ¸¡Ïõ.
3. ¿¡ÅÈðº¢Ôõ, ÅÂ¢üÚû ¸¡üÚì ÜÊô ¦ÀÕìÌõ. 
4. ¿£÷§Åð¨¸ Á¢ÌóÐ ÓôÀ¢½¢ò ¦¾¡¼Õõ.
5. º¢Ú¿£÷ô ¦ÀÕ¸¢ Æ¢óÐ Å¢ó¨¾ «Æ¢ìÌõ.
6. ÀÎì¨¸Â¢ø ¸¢¼ì¸¦Å¡ð¼Ð ãî¦ºÃ¢Ôõ.
7. Å¡öìÌÁðÊ Í¨ÅÂüÚô ¦ÀÕãîÍñ¼¡ö ¯¼ø §º¡Õõ. 
8. ¯¼Ä¢ø ¸Æ¨Ä, ¸ðÊ ¯ñ¼¡õ.
9. ¯¼Ä¢ø ÑñÒØì¸û ¯ñ¼¡ö ¯¼¨Ä ¦ÁÄ¢Âî ¦ºöÔõ. 
10. Ú¾¢Â¢ø ¨ªôÒ§¿¡ö ¯ñ¼¡öì ¦¸¡øÖõ.
The above complications occur in undiagnosed and improperly treated cases. 
The complications of madhumegam described in siddha text is really correlated with 
Diabetes mellitus in modern science. 
ÓìÌüÈ §ÅÚÀ¡Î¸û:
¾ýÅ¢¨É, À¢ÈÅ¢¨É¸ª¢ý «ªÅ¡¸ ³Âõ ¾ýÉ¢¨ÄÂ¢ø §¸¼¨¼óÐ 
¸£ú§¿¡ìÌí¸¡ø ¦¸ðÎ, «òÐ¼ý ¯¼ü¸ðÎ¸û ²¨ÆÔõ ´ýÈýÀ¢ý 
´ýÈ¡öì¦¸¼î ¦ºöÐ ¿¡ª¨¼Å¢ø Àº¢ò¾£¨Âì ¦¸ÎìÌõ. °ð¼õ ¾Õõ 
¦À¡Õû¸¨ª ¯ñ½¢Ûõ, ¯¼ø Åý¨ÁÂ¨¼Å¾¢ø¨Ä. Á¡È¡¸ì §¸¼¨¼ó¾ 
«ìÌüÈò¾¡ø ÁüÈ ÃñÎõ ¾ýÉ¢¨Ä À¢ÈúóÐ ¾í¸ÙìÌò Ð¨½Â¡öì 
¸¡ø(Å¡Ôì)¸¨ªÔõ ÜðÊ ²Ø ¯¼ü¸ðÎì¸ª¢ý Åý¨Á¨Âì ¦¸¼î¦ºöÐ 
ÀÄÅ¨¸ôÀð¼ §¿¡öì¨ªÔõ ó§¿¡öìÌò Ð¨½Â¡ìÌõ. ¾¨É, 
Ì¨ÈóÐ ÅÕõ ¾¡Ð¦ÅøÄ¡õ ÌýÈ¢ô§À¡Ìõ"XLVI
±ýÀ¾¡ø «È¢ÂÄ¡õ.
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MODERN ASPECT 
 
DIABETES MELLITUS
DEFINITION: 
Diabetes mellitus is a clinical syndrome characterized by hyperglycaemia due to 
absolute or relative deficiency of insulin. Lack of insulin affects the metabolism of 
carbohydrate , protein and fat and causes a singnificant disturbance of water and 
electrolyte homeostasis. 
 
EPIDEMIOLOGY: 
Diabetes is worldwide in distribution and the incidence of both type 1 and type 2 
diabetes is rising.  It is associated with several contributory factors including increased 
longevity, obesity, unsatisfactory diet, sedentary lifestyle and increasing urbanization. 
Diabetes is the single most important metabolic diseases of humans. It can affect nearly 
every organ system in the body, and is recognized as one of the leading causes of death 
and disability worldwide.
over 40 million individuals affected by this deadly disease. It is expected  to rise more 
rapidly in the future because of increasing obesity and reduced activity levels. 
However, the prevalence of both types of diabetes varies considerably around the 
world, and is related to differences in genetic and environmental factors. A pronounced 
rise in prevalence occurs in migrant populations to industrialized countries, e-g: Asian 
and Afro-Carribbean immigrants to the United Kingdom. The prevalence of known 
diabetes in Britain is around 2-3%. Many more cases of type 2 diabetes remain 
undetected. 
CLASSIFICATION: 
ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS: 
1.Type 1 diabetes (-cell destruction, usually leading to absolute insulin deficiency) 
A. Immune-mediated 
B. Idiopathic. 
2.Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly insulin secretory defect with insulin resistance)  
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3.Other specific types of diabetes 
 Genetic defects of cell function characterized by mutations in: 
 Hepatocyte nuclear transcription factor (HNF) 4 (MODY 1) 
 Glucokinase (MODY 2) 
 HNF-1 (MODY 3) 
 Insulin promoter factor (IPF) 1 (MODY 4) 
HNF-1 (MODY 5) 
 Mitochondrial DNA 
 Proinsulin or insulin conversion 
Genetic defects in insulin action 
 Type A insulin resistance 
 Leprechaunism 
 Rabson-Mendenhall syndrome
 Lipoatrophic diabetes 
 Diseases of the exocrine pancreas-pancreatitis, pancreatectomy,  neoplasia, 
cysticfibrosis, hemochromatosis, fibrocalculous  pancreatopathy 
 ome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
 Drug- or chemical-induced Vacor, pentamidine, nicotinic acid, glucocorticoids, 
thyroid hormone, diazoxide, -adrenergic agonists, thiazides, phenytoin, interferon, 
protease inhibitors, clozapine, beta blockers
Infections: congenital rubella, cytomegalovirus, coxsackie 
Uncommon forms of immune- - -
insulin receptor antibodies
Other genetic syndromes sometimes associated with diabetes: 
-Moon-Biedl 
syndrome,myotonic ystrophy, porphyria, Prader-Willi syndrome. 
4.Gestational diabetes mellitus (GDM) 
MODY : Maturity onset of diabetes of the young. 
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Diabetes mellitus (DM) describes a group of chronic metabolic disorders 
characterized by hyperglycemia that may result in long-term microvascular, 
macrovascular, and neuropathic complications. These complications contribute to 
diabetes being the leading cause of: (a) new cases of blindness among adults, (b) end-
stage renal disease, and (c) nontraumatic lower limb amputations. While prevention and 
treatment of DM remain a challenge, several studies have shown that complications 
associated with DM such as retinopathy and neuropathy can be delayed or prevented 
through proper blood glucose management. 
The increased cardiovascular risk associated with DM contributes to it being the 
sixth leading cause of death in the United States. In 2007, diabetes caused approximately 
284,000 deaths, accounted for more than 15 million workdays absent and an additional 
107 million workdays lost due to unemployment disability. The financial impact of DM 
in 2007 was approximately $174 billion, or one of every five dollars spent on health care 
in the United States.3 
EPIDEMIOLOGY AND ETIOLOGY: 
DM is characterized by a complete lack of insulin, a relative lack of insulin, or 
insulin resistance as well as disorders of other hormones. These defects result in an 
inability to use glucose for energy. DM affects an estimated 23.6 million persons in the 
United States, or 7% of the population. While an estimated 17.9 million persons have 
been diagnosed, another 5.7 million people have DM but are unaware they have the 
disease. Worldwide, the number of people with DM is expected to rise to 35% by the year 
2025.3 The increasing prevalence of DM is due in part to three influences: lifestyle, 
ethnicity, and age. 
Lifestyle: 
Sedentary lifestyle coupled with greater consumption of high-fat foods and larger 
portion sizes have resulted in increasing rates of persons being overweight or obese. 
Current estimates indicate that 65% of the U.S. population is overweight and of those, 
30% are obese. Overweight is defined as a body mass index ( BMI ) of greater than 25 
kg/m2, whereas a BMI of greater than 30 kg/m2 constitutes obesity. The Centers for 
Disease Control and Prevention (CDC) estimates that 25% to 33% of Americans do not 
engage in an adequate amount of daily activity.
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Ethnicity: 
In addition to current lifestyle trends and increased body weight, certain ethnic 
groups are at a disproportionately high risk for developing DM. Individuals of Native 
American, Native Alaskan, African American, and Hispanic/Latino American descent 
have 1.7 to 2.2 times greater risk of developing DM when compared with non-Hispanic 
whites.3 In addition, African American and Hispanic/Latino American populations are 
growing at a faster rate than the general U.S. population. This is a contributing factor to 
the rising U.S. population who has DM. 
Age: 
The third factor contributing to the increased prevalence of diabetes is age. The 
prevalence of DM increases with age from approximately 2% of individuals 20 to 39 
years of age to 20.9% of individuals older than 60 years of age.3 As the population ages, 
the incidence of DM is expected to increase. Type 2 DM (T2DM) accounts for 
approximately 90% to 95% of all diagnosed cases, is progressive in its development, and 
is often preceded by prediabetes. A combination of insulin deficiency, insulin resistance, 
and other hormonal irregularities, primarily glucagon, are key problems with T2DM. The 
majority of people with T2DM are overweight and an increasing number of cases in 
children have been observed.  
T2DM is usually slow and progressive in its development and is often preceded 
by prediabetes.
Risk factors for T2DM include:
-degree family history of DM (i.e., parents or siblings) 
ysical inactivity 
African American, and Pacific Islanders) 
impaired fasting glucose [IFG]) 
pertension (greater than or equal to 140/90 mm Hg) 
-density lipoprotein (HDL) less than 35 mg/dL (0.91 mmol/L) and/or a 
triglyceride level greater than 250 mg/dL (2.83 mmol/L) 
eighing greater than 4 kg ( 
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CLINICAL STUDY 
 
The pilot study on patients with Madhumegam (T2 Diabetes mellitus) and 
satisfying the inclusion criteria was conducted at the OPD, Ayothidoss Pandithar 
Hospital, National Institute of Siddha, Tambaram sanatorium, Chennai-47. 
Sample size:  
20 patients. 
 
SUBJECT SELECTION:  
Inclusion Criteria:  
 Age  : 30-60 years 
 Sex  : Both Male and Female  
 Patients having symptoms of,   
Dryness of mouth. 
Polyuria.  
Polyphagia 
Polydipsia  
Tiredness 
Recent change in weight 
Predilection for sweet foods 
(Any of the 4 or 5 clinical symptoms) 
-Patient who are willing to provide blood sample for investigation.
-Patient willing to attend OPD on every 7th day.
-Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 30 days but can opt out of the trial of his/her 
own conscious dissertation.
Exclusion Criteria:
Pregnancy and lactation
Cardiac disease
Renal disease
Liver disease
Known case of Hypo / hyper thyroidism
Any other serious illness
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Withdrawal Criteria:  
 Development of adverse reaction 
 Occurence of any other serious illness  
 Non co-operation of the patients  
 
TRIAL DRUG AND DURATION 
Drug:  
 Kandha Chenduram-130mg with Ghee  
Duration of the treatment:  
 30 days.  
 
Conduct study:
Madhumegam (T2 Diabetes mellitus) patients satisfying inclusion and exclusion 
criteria were attend to the trial. Informed consent was obtained from the patients. Routine 
investigations like Blood test, urine test, and PEFR were carried out before and after the 
trial treatment. For out patients the trial drug was issued for 7 days course. They were 
advised to visit the OPD once in 7 days. At each visit they were clinically assessed.  
 
Clinical observation: 
2 Diabetes 
mellitus), 20 patients were selected.
Among 20 patients, 10 (50 %) Patients were in Male, 10 (50%) Patients were in 
Female.
According to age wise distribution 15% Patients were in 30-40 years, 55% 
Patients were in 41-50 years and 30% Patients were in 51-60 years.
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DISCUSSION
 
 
The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to evaluate the therapeutic efficacy of the drug Kandha chenduram in the 
management of  Madhumegam (T2 Diabetes mellitus) 
As per Siddha text in Madhumegam, kabam humors were deranged. Kaba thathu 
is responsible for the functioning of the Udal thathukal uniformly.  
Hence administration of the trial drug Kandha chenduram was effective in the 
management of Madhumegam. 
The trial drug was studied as per OECD guidelines.  
Bio-chemical analysis of the trial drug was done and it shows the presence of 
Chloride, Iron, Calcium, Sodium and Amino acids
 
Toxicity Study
Based on these findings, toxic effect was observed at both 25 and 50mg/kg of 
Kandha Chenduram treated via oral route over a period of 28 days. So, it can be 
concluded that the Kandha Chenduram can be prescribed for therapeutic use in human 
with the strict dosage reductions of upto 12.5mg/kg. body weight p.o. 
Pharmacological Study
-
cells of the islets of Langerhans. Kandha Chenduram did not show any effect on normal 
blood sugar levels but it effectively reversed the alloxan-induced changes in the blood 
sugar level and the -cell population in the pancreas. This could be due to potentiation of 
the insulin effect of plasma by increasing the pancreatic secretion of insulin from existing 
-cells of islets of Langerhans or its release from bound insulin. Diabetes mellitus is 
possibly the world's largest growing metabolic disease, and as the knowledge on the 
heterogeneity of this disorder is advanced, the need for more appropriate therapy 
increases. Traditional medicines like Kandha Chenduram can be used for a range of 
diabetic complications with lesser side effects.
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Age  
 Among the 20 patient 55% of them were in the age group of 41-50. It reveals that 
mostly aged and middle age group peoples were affected.  
 
Sex 
All patients included were both Male and Female.  
 
Gunam And Diet 
All patients included in this study were having Thamo Gunam and they have non-
vegetarian diet regularly. 
 
Body Constitution 
All patients were observed to have Thondha Udal type of body constitution. 
 
Thinai 
In this study 75% of the patients were from Neithal Thinai and remaining 25% of 
people were from Kurinji Thinai. People from Neithal Thinai have more chances to 
develop deranged Pitham humor. 
 
Family History 
Among 20 patients, 55% of the patients show positive family history.
Occupational History 
Occupational history of the patients showing that
50% of them were businessman & salesman 
35% of them were farmers
15% of others. 
Socio-Economic Status 
Among 20 patients, 55% of Patients middle class, 25% of Patients high class and 
20% were from poor people.
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Naadi 
Among 20 patients, 60% were having vathapitha naadi, 30% were having 
pithavatha naadi and 10% were having vathakaba nadi.  
 
Clinical Symptoms 
Among 20 patients,  
85% of patients relieved from polyurea,  
65% of patients relieved from polyphagia,  
75% of patients relieved from polydypsia,  
70% of patients relieved from dryness of mouth.  
75% of patients relieved from general tiredness, and no adverse effects were 
observed during trial period. 
Investigations 
Among 20 patients the serum enzyme markers 
 Blood sugar (Fasting) level was significantly reduced in 70% of patients 
 Blood sugar (Post prandial) level was significantly reduced in 60% of patients. 
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SUMMARY 
 
 The literary evidence from the Siddha text, Kannusamy Parambarai Vaithyam 
strongly support the Hypoglycemic Activity of the drug. 
 The drug Kandha chenduram was selected to evaluate the Hypoglycemic  Activity 
in the management of Madhumegam (T2 Diabetes mellitus). 
The biochemical analysis of the drug reveals the presence of Chloride, Iron, 
Calcium, Sodium and Amino acids 
 The preclinical evaluation (acute & repeated oral toxicity study) of the drug was 
carried out as per OECD guideline in VELS University, Chennai. The result 
shows safety of the drug for human administration.
The Preclinical Pharmacological study was carried out in animal model in VELS 
University, Chennai. The result shows that the drug has significant Hypoglycemic
Activity of the drug.
 85% of patients relieved from polyuria,  
65% of patients relieved from polyphagia,  
75% of patients relieved from polydypsia,  
70% of patients relieved from dryness of mouth.  
75% of patients relieved from general tiredness,  
and no adverse effects were observed during trial period. 
The drug Kandha chenduram has
Hypoglycemic Activity & 
Encouraging clinical results.
From the pharmacological study and clinical, it is proved that the drug Kandha 
Chenduram is clinically significant on Hypoglycemic Activity in the management 
of Madhumegam (T2 Diabetes mellitus).
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CONCLUSION
 
 The Siddha literature and review of the research journals of the drugs shows that it 
has Hypoglycemic Activity. 
 The safety studies (acute and repeated oral toxicity) conducted revealed that the 
trial drug Kandha Chenduram was safe. There were no abnormalities found in 
blood investigation and histo-pathological examination. Hence it can be 
reasonably assumed that the drug is safe for human use. 
The pharmacological study conducted in animal model shows significant 
Hypoglycemic Activity.
Clinical study revealed the therapeutic efficacy of the trial drug was improvement 
the clinical symptoms before and after treatment. 
 Hence, the drug Kandha Chenduram can be used in the management of 
Madhumegam (T2 Diabetes mellitus).  
 
 
 
 
  
PRELIMINARY QUALITATIVE BIO-CHEMICAL TESTS RESULTS 
(SARAKONRAIPOO CHOORANAM) 
Table - 1 
S.NO CONSITUENTS INFERENCE
1. Sulphate Absent 
2. Chloride Absent
3. Phosphate Present 
4. Carbonate Absent 
5. Amino Acid Present 
6. Sulphide Absent 
7. Fluoride& Oxalate Absent
8. Borate Absent 
9. Lead Absent 
10. Copper Absent 
11. Aluminium Absent
12 Iron Present
13 Zinc Absent
15 Calcium Absent
16 Magnesium Absent
17 Ammonium Absent
18 Mercury Absent
19 Arsenic Absent
20 Alkaloids Present
21 Potassium Absent
22 Sodium Present
23 Starch Absent
PHYSICOCHEMICAL PROPERTIES  
 
 
 
 
Table-2. 
Colour characters of Sarakonraipoochooranam. 
 
 
S No 
 
Solvent used 
 
Under ordinary light 
 
Under ultra violet light 
 
1 PPM Brownish Yellow Brownish Yellow 
PPM-Powdered plant material 
 
 
 
 
Table-3. 
Physicochemical properties of Sarakonraipoochooranam. 
 
 
S No. 
 
Parameters  
Values 
obtained 
(%w/w) 
Heavy/ toxic metals 
1 Total ash value 9.87 Lead BDL 
2 Acid insoluble ash 0.7 Cadmium BDL 
3 Water soluble ash 9.8 Mercury BDL 
4 Moisture content 8.7 Arsenic BDL 
5 Foreign organic matter 5.2 
6 Crude fibre content 10.5 
SARAKONRAIPOO CHOORANAM -TLC/GC(PEAKS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-4
Colour, nature and percent yields of extracts of SarakonraipooChooranam. 
S.no Extract 
Solvents
Colour TLC/
GC
(PEA
KS)
Nature % 
Yield(w/w)
Optical-Micro 
graph partical 
size range in 
micron
 
pH 
1 Water Brownish 
Yellow
5 Solid 52 80 - 100 
micron 
7.8 - 8.1 
  
 
Table-5 
 
 
PRELIMINARY PHYTOCHEMICAL ANALYSIS OF DIFFERENT 
EXTRACTS OF SARAKONRAIPOO CHOORANAM. 
 
 
 
S.no 
 
Phytoconstituents 
 
Aqueous 
 
1 Alkaloids + 
2 Flavonoids + 
3 Glycosides + 
4 Amino acids + 
5 Triterpenoids + 
+ = Present, = Absent. 
 












Concentration in U/L
Concentration in mg/dl
Concentration in mg/dl
CLINICAL OBSERVATION 
 
 
AGE DISTRIBUTION         
           
          
 
 
 
GENDER DISTRIBUTION 
10, 50%
7, 35%
3, 15%
Age & No. of Pt’s
30 - 40
41 - 50
51 -60
16 
(80%)
4 (20%)
Gender
Male
Female
Age No. of pt’s % 
30 - 40 10 50 
41 - 50 7 35 
51 -60 3 15 
Sex No. of Pt’s %
Male 16 80
Female 4 20
IMPROVEMENT SHOWING SIGNS AND SYMPTOMS BEFORE 
AND AFTER TREATMENT OF KAMALAI 
 
 
Table – 17 
 
Symptoms 
Before Treatment After Treatment 
No. of Pt’s Percentage % No. of Pt’s 
Percentage 
% 
Malaise 14 70 1 5 
Anorexia 16 80 1 5 
Nausea 18 90 4 20 
Vomiting 19 95 2 10 
Jaundice 19 95 3 15 
Upper abdominal 
pain 18 90 2 10 
0
2
4
6
8
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14
16
18
20
14
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18 19 19 18
1 1
4
2 3 2 Before Treatment
After Treatment








TABLE - 22 
PRELIMINARY QUALITATIVE BIO-CHEMICAL TESTS RESULTS FOR 
KANDHA CHENDURAM 
S.NO CONSITUENTS INFERENCE
1. Calcium Present 
2. Sulphate Absent
3. Chloride Present 
4. Carbonate Absent
5. Sodium Present 
6. Iron  Present 
7. Phosphate Absent
8. Tannic acid Absent 
9. Sugars Absent 
10. Tannins Absent 
11. Alkaloids Present 
12 Fluoride Absent
13 Oxalate Absent
15 Zinc Absent
16 Magnesium Absent
17 Ammonium Absent
18 Mercury Absent
19 Arsenic Absent
20 Silicate Present
21 Lead Absent
22 Copper Absent
23 Starch absent
Physio – chemical properties 
 
Table-23.
 
 
Colour  characters of KandhaChenduram 
 
. 
 
S No 
 
Solvent used 
 
Under ordinary light 
 
Under ultra violet light 
 
1 PM Brown Brown 
PM-Powdered material 
 
Table-24.
Physicochemical properties of KandhaChenduram 
 
 
 
S No. 
 
Parameters  
Values 
obtained 
(%w/w) 
Heavy/ toxic metals 
1 Total ash value 9.75 Lead BDL 
2 Acid insoluble ash 0.75 Cadmium BDL 
3 Water soluble ash 8.4 Mercury BDL 
4 Moisture content  9.4 Arsenic BDL 
5 Loss on drying at 105°C 3.4   
Table-25.
Colour, nature and percent yields of extracts of  KandhaChenduram 
 
 
S.no. 
 
Extract 
Solvents
Colour Nature % Yield(w/w) 
Optical-Micro 
graph partical 
size range in 
micron 
pH 
1 Water brown Solid 46 30 - 50 micron 8.5 – 8.9 
SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY IITM,CHENNAI-36 PERKIN ELMER OPTIMA 5300DV ICP-OES 
 
     
Table - 26 
 
 
Sample ID 
 
Kandha Chenduram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BDL=Below  detection limit  
Analytical Mean 
As 193.696 BDL 
Ca 317.933 10.954 mg/L 
Cd 317.933 BDL 
Fe 238.204 75.632 mg/L 
Hg 253.652 BDL 
K 766.491 25.112 mg/L 
Mg 257.610 12.415 mg/L 
Na 588.995 17.245 mg/L 
P 214.914 15.247 mg/L 
Pb 230.204 BDL 
S 181.975 11.548 mg/L 














Blood glucose (mg/dl)
Body weight in Gms
Glucose (mg/dl) 
Concentration (mg/dl)
CLINICAL ASSESSMENT FOR KANDHA CHENDURAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age No. of patients Percentage % 
30 - 40 3 15 
41 - 50 11 55 
51 -60 6 30 
Sex No. of patients Percentage % 
Male 10 50 
Female 10 50 
3 (15%)
11 (55%)
6 (30%)
Age
30 - 40
41 - 50
51 -60
10, 50%
10, 50%
Gender
Male
Female
  
 
IMPROVEMENT SHOWING SIGNS AND SYMPTOMS BEFORE 
AND AFTER TREATMENT OF MADHUMEGAM 
  
Table - 41 
Symptoms 
Before Treatment After Treatment 
Pt’s Percentage % Pt’s Percentage % 
Polyurea 19 95 2 10 
Polyphagia 16 80 3 15 
Polydypsia 17 85 2 10 
Dryness of mouth 16 80 2 10 
General tiredness 18 90 3 15 
0
2
4
6
8
10
12
14
16
18
20
19
16 17 16
18
2 3 2 2 3
before treatment
after treatment









 
STATISTICAL  ANALYSIS: 
 
All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. SPSS software was used to perform 
statistical analysis. Basic descriptive statistics include frequency distributions and 
cross-tabulations were performed. The quantity variables were expressed as Mean ± 
Standard Deviation and qualitative data as percentage. A probability value of <0.05 
was considered to indicate as statistical significance. Paired ‘t’ test was performed for 
determining the significance between before and after treatment. 
 
 
TRIAL DRUG - I 
 
Paired t test for Total bilirubin before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 
20 1.615 .7555 
12.074 P<0.0001 
After 
treatment 20 1.185 .7513 
 
For Total bilirubin, the mean±standard deviation before treatment is 
1.615±0.7555 and after treatment is 1.185±0.7513, which is statistically 
significant(p<0.0001). 
Paired t test for Direct bilirubin before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before treatment 20 .670 .2536 
7.768 P<0.0001 
After treatment 20 .500 .2362 
For Direct bilirubin, the mean±standard deviation before treatment is 
0.670±0.2536 and after treatment is 0.500±0.2362, which is statistically 
significant(p<0.0001). 
 
 
 
 
Paired t test for InDirect bilirubin before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 
20 0.950 0.5176 
9.668 P<0.0001 
After treatment 20 0.685 0.5354 
 
For InDirect bilirubin, the mean±standard deviation before treatment is 
0.950±0.5176 and after treatment is 0.685±0.5354, which is statistically 
significant(p<0.0001). 
 
Paired t test for SGOT before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 
20 
 
44.50 
 
13.403 
 
9.162 P<0.0001 
After treatment 20 37.15 13.204 
For SGOT, the mean±standard deviation before treatment is 44.50±13.403 and 
after treatment is 37.15±13.204, which is statistically significant(p<0.0001). 
Paired t test for SGPT before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 
20 39.15 10.384 
9.992 P<0.0001 
After treatment 20 31.60 10.932 
For SGPT, the mean±standard deviation before treatment is 39.15± 10.384 
and after treatment is 31.60±10.932, which is statistically significant(p<0.0001). 
TRIAL DRUG - II 
STATISTICAL  ANALYSIS: 
 
All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. SPSS software was used to perform 
statistical analysis. Basic descriptive statistics include frequency distributions and 
cross-tabulations were performed. The quantity variables were expressed as Mean ± 
Standard Deviation and qualitative data as percentage. A probability value of <0.05 
was considered to indicate as statistical significance. Paired ‘t’ test was performed for 
determining the significance between before and after treatment. 
 
 
Paired t test for FBS before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 20 153.80 21.623 
9.126 P<0.0001 After 
treatment 20 114.80 22.430 
 
For FBS, the mean±standard deviation before treatment is 153.80± 21.623 and 
after treatment is 114.80±22.430, which is statistically significant(p<0.0001). 
Paired t test for PPBS before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 20 232.95 34.195 
12.230 P<0.0001 After 
treatment 20 151.80 28.164 
For PPBS, the mean±standard deviation before treatment is 232.95± 34.195 
and after treatment 151.80±28.164, which is statistically significant(p<0.0001). 
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